US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20040033977A1
(en)
*
|
1990-08-14 |
2004-02-19 |
Bennett C. Frank |
Oligonucleotide modulation of cell adhesion
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
WO1993023569A1
(en)
*
|
1992-05-11 |
1993-11-25 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting viral replication
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US6156535A
(en)
*
|
1995-08-04 |
2000-12-05 |
University Of Ottawa |
Mammalian IAP gene family, primers, probes, and detection methods
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US6274369B1
(en)
*
|
1996-02-02 |
2001-08-14 |
Invitrogen Corporation |
Method capable of increasing competency of bacterial cell transformation
|
US6133437A
(en)
*
|
1997-02-13 |
2000-10-17 |
Apoptogen, Inc. |
Modulation of IAPs for the treatment of proliferative diseases
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20060008448A1
(en)
*
|
1996-06-11 |
2006-01-12 |
Minzhen Xu |
Inhibition of li expression in mammalian cells
|
US20040072345A1
(en)
*
|
1997-06-20 |
2004-04-15 |
Altaba Ariel Ruiz I. |
Method and compositions for inhibiting tumorigenesis
|
US7709454B2
(en)
*
|
1997-06-20 |
2010-05-04 |
New York University |
Methods and compositions for inhibiting tumorigenesis
|
US6238876B1
(en)
*
|
1997-06-20 |
2001-05-29 |
New York University |
Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
|
NZ520579A
(en)
*
|
1997-10-24 |
2004-08-27 |
Invitrogen Corp |
Recombinational cloning using nucleic acids having recombination sites and methods for synthesizing double stranded nucleic acids
|
US7351578B2
(en)
|
1999-12-10 |
2008-04-01 |
Invitrogen Corp. |
Use of multiple recombination sites with unique specificity in recombinational cloning
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
FR2782325B1
(en)
|
1998-08-12 |
2002-05-24 |
Proteus |
METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS
|
US20060260005A1
(en)
*
|
1998-02-26 |
2006-11-16 |
Zhizhen Chen |
Transformation of Brassica
|
US20040045056A1
(en)
*
|
1998-02-26 |
2004-03-04 |
Zhizheng Chen |
Transformation of Brassica
|
CA2325344C
(en)
†
|
1998-04-08 |
2017-12-05 |
Commonwealth Scientific And Industrial Research Organisation |
Methods and means for obtaining modified phenotypes
|
US8598332B1
(en)
*
|
1998-04-08 |
2013-12-03 |
Bayer Cropscience N.V. |
Methods and means for obtaining modified phenotypes
|
US20040214330A1
(en)
*
|
1999-04-07 |
2004-10-28 |
Waterhouse Peter Michael |
Methods and means for obtaining modified phenotypes
|
US20030228597A1
(en)
*
|
1998-04-13 |
2003-12-11 |
Cowsert Lex M. |
Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|
WO1999054459A2
(en)
*
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
US7078224B1
(en)
*
|
1999-05-14 |
2006-07-18 |
Promega Corporation |
Cell concentration and lysate clearance using paramagnetic particles
|
AR020078A1
(en)
*
|
1998-05-26 |
2002-04-10 |
Syngenta Participations Ag |
METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
|
US7019195B1
(en)
*
|
1998-05-26 |
2006-03-28 |
Syngenta Participations Ag |
Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
|
US7005423B1
(en)
*
|
1999-07-02 |
2006-02-28 |
Devgen Nv |
Characterization of gene function using double stranded RNA inhibition
|
GB9827152D0
(en)
*
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
US20040242521A1
(en)
*
|
1999-10-25 |
2004-12-02 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US20060172925A1
(en)
*
|
1998-10-26 |
2006-08-03 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US6759574B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Plants having enhanced gall resistance and methods and compositions for producing same
|
US6939712B1
(en)
*
|
1998-12-29 |
2005-09-06 |
Impedagen, Llc |
Muting gene activity using a transgenic nucleic acid
|
EP1147204A1
(en)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(en)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Method and medicament for inhibiting the expression of a given gene
|
AU2008202208C1
(en)
*
|
1999-01-30 |
2014-04-24 |
Alnylam Pharmaceuticals, Inc. |
Method and medicament for inhibiting the expression of a defined gene
|
US6987025B1
(en)
|
1999-02-11 |
2006-01-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Dwf4 polynucleotides, polypeptides and uses thereof
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
EP1169480A4
(en)
*
|
1999-04-14 |
2005-02-02 |
Musc Found For Res Dev |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
BR0009884A
(en)
*
|
1999-04-21 |
2002-01-08 |
American Home Prod |
Processes and compositions for inhibiting the function of polynucleotide sequences
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
WO2000068374A1
(en)
*
|
1999-05-10 |
2000-11-16 |
Syngenta Participations Ag |
Regulation of viral gene expression
|
WO2000073493A2
(en)
*
|
1999-05-27 |
2000-12-07 |
Pharmacia & Upjohn |
A nematode drug screen for modulators of mammalian disorders
|
US7485715B2
(en)
|
1999-06-18 |
2009-02-03 |
Ceres, Inc. |
Sequence-determined DNA encoding AP2 domain polypeptides
|
US20040002153A1
(en)
*
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
US7479555B2
(en)
|
1999-07-21 |
2009-01-20 |
Ceres, Inc. |
Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
|
CA2379819A1
(en)
|
1999-07-29 |
2001-02-08 |
Dana-Farber Cancer Institute, Inc. |
Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
|
US6924109B2
(en)
*
|
1999-07-30 |
2005-08-02 |
Agy Therapeutics, Inc. |
High-throughput transcriptome and functional validation analysis
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US6822086B1
(en)
*
|
1999-08-09 |
2004-11-23 |
The General Hospital Corporation |
Drug-carrier complexes and methods of use thereof
|
BR0013607A
(en)
|
1999-08-26 |
2002-04-30 |
Calgene Llc |
Nucleic acid sequences and processes of use for the production of plants with modified polyunsaturated fatty acids
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US20040106567A1
(en)
*
|
1999-09-07 |
2004-06-03 |
Hagstrom James E. |
Intravascular delivery of non-viral nucleic acid
|
US20020006664A1
(en)
*
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
JP2003516124A
(en)
|
1999-10-15 |
2003-05-13 |
ユニバーシティー オブ マサチューセッツ |
RNA interference pathway genes as a means of targeted genetic interference
|
US20040157327A1
(en)
*
|
1999-10-22 |
2004-08-12 |
Wyeth |
Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10100586C1
(en)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10160151A1
(en)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
|
US20050229272A1
(en)
*
|
1999-12-30 |
2005-10-13 |
Monica Driscoll |
Compositions and methods for gene silencing
|
IL150484A0
(en)
*
|
1999-12-30 |
2002-12-01 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
US6531644B1
(en)
|
2000-01-14 |
2003-03-11 |
Exelixis, Inc. |
Methods for identifying anti-cancer drug targets
|
US7179796B2
(en)
*
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
JP2003525037A
(en)
*
|
2000-02-11 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Methods and reagents for regulation and diagnosis of CD20 and NOGO gene expression
|
US7491805B2
(en)
*
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
EP1272630A2
(en)
*
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
US8202846B2
(en)
*
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
EP1728862A1
(en)
*
|
2000-03-16 |
2006-12-06 |
Genetica, Inc. |
Methods and compositions for RNA interference
|
KR20020097198A
(en)
*
|
2000-03-17 |
2002-12-31 |
베니텍 오스트레일리아 리미티드 |
Genetic silencing
|
PT2028278E
(en)
†
|
2000-03-30 |
2014-05-28 |
Max Planck Ges Zur Förderung Der Wissenschaften E V |
Rna sequence-specific mediators of rna interference
|
ATE450621T2
(en)
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
MEDIATORS OF RNA INTERFERENCE THAT ARE RNA SEQUENCE SPECIFIC
|
US7691991B2
(en)
|
2000-04-17 |
2010-04-06 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding cytochrome P450 proteins
|
GB0012233D0
(en)
|
2000-05-19 |
2000-07-12 |
Devgen Nv |
Vector constructs
|
EP1290161B1
(en)
*
|
2000-05-30 |
2011-06-22 |
Johnson & Johnson Research Pty Limited |
METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
|
JP2002306183A
(en)
*
|
2000-06-02 |
2002-10-22 |
Mitsubishi Chemicals Corp |
Method for identifying gene function
|
WO2001096584A2
(en)
*
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
WO2002000904A2
(en)
|
2000-06-23 |
2002-01-03 |
E. I. Du Pont De Nemours And Company |
Recombinant constructs and their use in reducing gene expression
|
US7662791B2
(en)
|
2000-08-02 |
2010-02-16 |
University Of Southern California |
Gene silencing using mRNA-cDNA hybrids
|
US8044259B2
(en)
*
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
CA2456008A1
(en)
*
|
2000-08-19 |
2002-02-28 |
Axordia Limited |
Stem cell differentiation
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US20060247194A1
(en)
*
|
2000-08-30 |
2006-11-02 |
Sirna Therapeutics , Inc. |
Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US7429457B2
(en)
*
|
2000-09-14 |
2008-09-30 |
The Regents Of The University Of California |
Id-1 and Id-2 genes and products as markers of epithelial cancer
|
US20020165192A1
(en)
*
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
US20020137711A1
(en)
*
|
2000-09-19 |
2002-09-26 |
Kerr William G. |
Control of NK cell function and survival by modulation of SHIP activity
|
US7691821B2
(en)
*
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
AU3237902A
(en)
*
|
2000-10-12 |
2002-04-29 |
New York Health Res Inst |
Oligonucleotide - facilitated coalescence
|
CA2427347C
(en)
|
2000-10-31 |
2011-01-18 |
Commonwealth Scientific And Industrial Research Organisation |
Method and means for producing barley yellow dwarf virus resistant cereal plants
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
CH695778A5
(en)
*
|
2000-11-29 |
2006-08-31 |
Hoffmann La Roche |
Inhibition of transcription of a target gene in a cell or in tissues.
|
HU230458B1
(en)
*
|
2000-12-01 |
2016-07-28 |
Europäisches Laboratorium für Molekularbiologie (EMBL) |
Rna interference mediating small rna molecules
|
JP2004532616A
(en)
*
|
2000-12-28 |
2004-10-28 |
ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド |
Double-stranded RNA-mediated gene suppression
|
US7385046B2
(en)
|
2001-01-03 |
2008-06-10 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding ethylene responsive element binding proteins
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP1860199B1
(en)
|
2001-01-12 |
2014-03-05 |
Exelixis, Inc. |
Modulating insulin receptor signaling
|
JP2002208294A
(en)
*
|
2001-01-12 |
2002-07-26 |
Toshiba Corp |
Semiconductor memory having redundancy system
|
CA2429397C
(en)
|
2001-01-26 |
2014-06-03 |
Commonwealth Scientific And Industrial Research Organisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
EP1229134A3
(en)
*
|
2001-01-31 |
2004-01-28 |
Nucleonics, Inc |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
WO2002062989A2
(en)
*
|
2001-02-08 |
2002-08-15 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
US7563618B2
(en)
|
2001-03-23 |
2009-07-21 |
Geron Corporation |
Oligonucleotide conjugates
|
EP1386004A4
(en)
*
|
2001-04-05 |
2005-02-16 |
Ribozyme Pharm Inc |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
WO2003072590A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20070049543A1
(en)
*
|
2001-05-18 |
2007-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050170371A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
WO2003070972A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
WO2003070897A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
JP4358521B2
(en)
|
2001-05-18 |
2009-11-04 |
サーナ・セラピューティクス・インコーポレイテッド |
Conjugates and compositions for cellular delivery
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
EP1390472A4
(en)
*
|
2001-05-29 |
2004-11-17 |
Sirna Therapeutics Inc |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
JP2005501528A
(en)
|
2001-06-05 |
2005-01-20 |
エクセリクシス・インコーポレイテッド |
GFATs as p53 pathway modifiers and methods of use
|
EP1406489A4
(en)
*
|
2001-06-22 |
2005-08-24 |
Univ California |
Eukaryotic genes involved in adult lifespan regulation
|
AUPR621501A0
(en)
|
2001-07-06 |
2001-08-02 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of ds rna
|
US20040126867A1
(en)
*
|
2001-07-06 |
2004-07-01 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
ES2192945B1
(en)
*
|
2001-07-06 |
2005-03-01 |
Consejo Superior De Investigaciones Cientificas |
A METHOD TO INTERFER WITH VIRUS INFECTION IN PLANTS.
|
US7345025B2
(en)
*
|
2001-07-10 |
2008-03-18 |
Johnson & Johnson Research Pty. Limited |
Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
|
KR101021695B1
(en)
*
|
2001-07-12 |
2011-03-15 |
유니버시티 오브 매사추세츠 |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
AU2002316631A1
(en)
|
2001-07-12 |
2003-01-29 |
Exelixis, Inc. |
Ube2s as modifiers of the p21 pathway and methods of use
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
US10590418B2
(en)
*
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
CA2936534C
(en)
*
|
2001-07-23 |
2021-01-26 |
The Board Of Trustees Of Leland Stanford Junior University |
Methods and compositions for rnai mediated inhibition of gene expression in mammals
|
US7612194B2
(en)
*
|
2001-07-24 |
2009-11-03 |
Monsanto Technology Llc |
Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
|
GB0118223D0
(en)
*
|
2001-07-26 |
2001-09-19 |
Univ Sheffield |
Stem loop RNA
|
US20050037989A1
(en)
*
|
2001-08-27 |
2005-02-17 |
Lewis David L. |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
US7456335B2
(en)
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
US7737124B2
(en)
|
2001-09-13 |
2010-06-15 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
|
JP4344858B2
(en)
|
2001-09-13 |
2009-10-14 |
カリフォルニア インスティチュート オブ テクノロジー |
Methods for expressing small antiviral RNA molecules in cells
|
US7195916B2
(en)
*
|
2001-09-13 |
2007-03-27 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules within a cell
|
EP1446503A2
(en)
|
2001-09-27 |
2004-08-18 |
University Of Delaware |
Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
|
EP2385122B1
(en)
|
2001-09-28 |
2018-04-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
MicroRNA molecules
|
GB0123401D0
(en)
*
|
2001-09-28 |
2001-11-21 |
Novartis Forschungsstiftung |
Methods of inducing gene expression
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10163098B4
(en)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Method for inhibiting the replication of viruses
|
WO2003034985A2
(en)
*
|
2001-10-22 |
2003-05-01 |
University Of Rochester |
Telomerase interference
|
WO2003035083A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Drug for treating a fibrotic disease through rna interfence
|
DE10230996A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Method for inhibiting viral replication, useful particularly for treating hepatitis C infection, by altering the 3'-untranslated region of the virus
|
US20040248835A1
(en)
*
|
2001-10-26 |
2004-12-09 |
Anja Krebs |
Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
|
DE10230997A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
JP2005527639A
(en)
*
|
2001-11-02 |
2005-09-15 |
インサート セラピューティクス インコーポレイテッド |
Methods and compositions for therapeutic use of RNA interference
|
CN1318586C
(en)
*
|
2001-11-05 |
2007-05-30 |
詹森药业有限公司 |
Method for the in vitro synthesis of short double stranded RNAs
|
US20030150017A1
(en)
*
|
2001-11-07 |
2003-08-07 |
Mesa Jose Ramon Botella |
Method for facilitating pathogen resistance
|
US20030148519A1
(en)
*
|
2001-11-14 |
2003-08-07 |
Engelke David R. |
Intracellular expression and delivery of siRNAs in mammalian cells
|
EP1456647A4
(en)
*
|
2001-11-19 |
2006-10-18 |
Proteologics Inc |
Methods for identifying and validating potential drug targets---
|
CN1612930A
(en)
*
|
2001-11-21 |
2005-05-04 |
三菱化学株式会社 |
Method of inhibiting gene expression
|
AU2002343792A1
(en)
*
|
2001-11-28 |
2003-06-10 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
GB0130199D0
(en)
*
|
2001-12-17 |
2002-02-06 |
Syngenta Mogen Bv |
New nematode feeding assay
|
US7294504B1
(en)
*
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
DE10202419A1
(en)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Method of inhibiting expression of a target gene resulting from chromosome aberration
|
AU2008246266B2
(en)
*
|
2002-01-22 |
2012-09-06 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
AU2012261651B2
(en)
*
|
2002-01-22 |
2015-09-24 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
EP1478656B1
(en)
|
2002-02-01 |
2009-09-16 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
WO2003064621A2
(en)
*
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030203868A1
(en)
*
|
2002-02-06 |
2003-10-30 |
Bushman Frederic D. |
Inhibition of pathogen replication by RNA interference
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
WO2003068961A2
(en)
*
|
2002-02-13 |
2003-08-21 |
Axordia Limited |
Method to modify differentiation of pluripotential stem cells
|
ES2312753T5
(en)
*
|
2002-02-14 |
2012-12-13 |
City Of Hope |
Procedures for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
EP1448590A4
(en)
*
|
2002-02-20 |
2004-12-15 |
Sirna Therapeutics Inc |
Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
JP2005517423A
(en)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
RNA interference-mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acids (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
WO2003070966A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US20090137513A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
AU2003215161A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7893248B2
(en)
*
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
AU2003219817B2
(en)
|
2002-02-20 |
2006-08-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US7662952B2
(en)
*
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
EP1484393A4
(en)
*
|
2002-02-22 |
2005-08-10 |
Otsuka Pharma Co Ltd |
Polynucleotide for target gene
|
US20050176008A1
(en)
*
|
2002-02-22 |
2005-08-11 |
Mikio Suzuki |
Polynucleotide for target gene
|
AUPS078002A0
(en)
*
|
2002-02-27 |
2002-03-21 |
Unisearch Limited |
Dnazyme therapeutics
|
EP2277522B1
(en)
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Methods for increasing or decreasing bone density and identifying molecules
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
EP2258712A3
(en)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
WO2003078595A2
(en)
*
|
2002-03-15 |
2003-09-25 |
Astral, Inc. |
Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
|
WO2003079025A2
(en)
|
2002-03-19 |
2003-09-25 |
Novartis Ag |
Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
|
DE10212893A1
(en)
*
|
2002-03-20 |
2003-10-16 |
Basf Plant Science Gmbh |
Process for increasing the oil content in plants
|
DE10212892A1
(en)
|
2002-03-20 |
2003-10-09 |
Basf Plant Science Gmbh |
Constructs and methods for regulating gene expression
|
US7166771B2
(en)
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
EP2294915A3
(en)
*
|
2002-03-21 |
2011-04-13 |
Monsanto Technology LLC |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
EP1490490B1
(en)
*
|
2002-03-27 |
2009-05-13 |
Aegera Therapeutics Inc. |
Antisense iap nucleobase oligomers and uses thereof
|
US7541150B2
(en)
*
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
EP1352960A1
(en)
*
|
2002-04-12 |
2003-10-15 |
Viruvation B.V. |
Antiviral therapy on the basis of RNA interference
|
WO2003087368A2
(en)
*
|
2002-04-18 |
2003-10-23 |
Lynkeus Bio Tech Gmbh |
Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
|
US7226771B2
(en)
|
2002-04-19 |
2007-06-05 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
WO2003089620A2
(en)
|
2002-04-19 |
2003-10-30 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
US6790641B2
(en)
|
2002-05-01 |
2004-09-14 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
DK1504126T3
(en)
*
|
2002-05-03 |
2014-06-10 |
Univ Duke |
PROCEDURE FOR REGULATING GENEPRESSION
|
EP2298358A1
(en)
|
2002-05-06 |
2011-03-23 |
Alnylam Pharmaceuticals Inc. |
Methods for delivery of nucleic acids
|
US20030228691A1
(en)
*
|
2002-05-17 |
2003-12-11 |
Lewis David L. |
Processes for inhibiting gene expression using polynucleotides
|
US7351542B2
(en)
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
AU2003283951A1
(en)
*
|
2002-05-23 |
2004-03-03 |
Ceptyr, Inc. |
Modulation of biological signal transduction by rna interference
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
US20040019008A1
(en)
*
|
2002-05-28 |
2004-01-29 |
Lewis David L. |
Compositions and processes using siRNA, amphipathic compounds and polycations
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
FR2840217B1
(en)
*
|
2002-06-03 |
2005-06-24 |
Oreal |
COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DSRNA) AND USES THEREOF
|
AUPS282602A0
(en)
|
2002-06-07 |
2002-06-27 |
Garvan Institute Of Medical Research |
Method of inhibiting cell proliferation
|
CA2388441A1
(en)
*
|
2002-06-10 |
2003-12-10 |
Wei-Ping Min |
Immunomodulation using rna interference
|
WO2003106631A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Ambion, Inc. |
Methods and compositions relating to labeled rna molecules that reduce gene expression
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
KR20050010053A
(en)
|
2002-06-14 |
2005-01-26 |
다이버사 코포레이션 |
Xylanases, nucleic acids encoding them and methods for making and using them
|
WO2004001000A2
(en)
*
|
2002-06-21 |
2003-12-31 |
Monsanto Technology Llc |
Intron double stranded rna constructs and uses thereof
|
WO2004003554A1
(en)
*
|
2002-06-26 |
2004-01-08 |
University Of Louisville Research Foundation, Inc. |
A method for the detection of apoptosis
|
JP2005537028A
(en)
*
|
2002-06-26 |
2005-12-08 |
ザ ペン ステート リサーチ ファウンデーション |
Methods and materials for treating human papillomavirus infections
|
AU2003247951A1
(en)
*
|
2002-07-10 |
2004-01-23 |
Kansas State University Research Foundation |
Compositions and methods for controlling parasitic nematodes
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
JP2005532829A
(en)
*
|
2002-07-18 |
2005-11-04 |
インヴィトロジェン コーポレーション |
Viral vectors containing recombination sites
|
DE10233327A1
(en)
*
|
2002-07-22 |
2004-02-05 |
Basf Ag |
Process for achieving pathogen resistance in plants
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
EP1527183B1
(en)
|
2002-07-26 |
2008-08-20 |
BASF Plant Science GmbH |
Novel selection method
|
US20050058982A1
(en)
|
2002-07-26 |
2005-03-17 |
Chiron Corporation |
Modified small interfering RNA molecules and methods of use
|
AU2003274906A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Nucleonics, Inc. |
Double stranded rna structures and constructs, and methods for generating and using the same
|
US8389244B2
(en)
*
|
2002-08-01 |
2013-03-05 |
City Of Hope |
Methods and kits for synthesis of siRNA expression cassettes
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
SI2258847T1
(en)
|
2002-08-05 |
2017-08-31 |
Silence Therapeutics Gmbh |
Futher novel forms of interfering RNA molecules
|
US20080176812A1
(en)
*
|
2002-08-05 |
2008-07-24 |
Davidson Beverly L |
Allele-specific silencing of disease genes
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
US20080274989A1
(en)
*
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20050042646A1
(en)
*
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20050106731A1
(en)
*
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
SG166672A1
(en)
*
|
2002-08-06 |
2010-12-29 |
Intradigm Corp |
Methods of down regulating target gene expression in vivo by introduction of interfering rna
|
EP1529112A2
(en)
|
2002-08-07 |
2005-05-11 |
BASF Plant Science GmbH |
Nucleic acid sequences encoding proteins associated with abiotic stress response
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
CN1685063B
(en)
*
|
2002-08-12 |
2011-12-21 |
新英格兰生物实验室公司 |
Methods and compositions relating to gene silencing
|
EP1534832A2
(en)
*
|
2002-09-04 |
2005-06-01 |
Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin |
Compositions and methods for tissue specific or inducible inhibition of gene expression
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
AU2003268531A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
WO2004024919A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
AU2003270734A1
(en)
*
|
2002-09-16 |
2004-04-30 |
University Of Southern California |
Rna-mediated gene modulation
|
US7476777B2
(en)
|
2002-09-17 |
2009-01-13 |
Ceres, Inc. |
Biological containment system
|
WO2004027030A2
(en)
*
|
2002-09-18 |
2004-04-01 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
|
AU2003282877B9
(en)
|
2002-09-25 |
2011-05-12 |
University Of Massachusetts |
In Vivo gene silencing by chemically modified and stable siRNA
|
AU2003277005A1
(en)
*
|
2002-09-26 |
2004-04-19 |
The Regents Of The University Of California |
Conditional gene expression using rnai
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
US20070224124A1
(en)
*
|
2002-09-30 |
2007-09-27 |
University Of South Florida |
Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
|
AU2003275449A1
(en)
*
|
2002-10-07 |
2004-05-04 |
Wei Liu |
Compositions, organisms and methodologies employing a novel human kinase
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
PL211654B1
(en)
*
|
2002-10-08 |
2012-06-29 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
US7255860B2
(en)
*
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
EP1575518A4
(en)
*
|
2002-10-10 |
2007-08-22 |
Wyeth Corp |
Compositions, organisms and methodologies employing a novel human kinase
|
CN1720327A
(en)
*
|
2002-10-10 |
2006-01-11 |
惠氏公司 |
Compositions, organisms and methodologies employing a novel human kinase
|
AU2003301348A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Wyeth |
Compositions and methods for diagnosing and treating autoimmune disease
|
CA2503491A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Wyeth |
Calcineurin-like human phosphoesterase
|
NZ540779A
(en)
*
|
2002-11-01 |
2008-05-30 |
Univ Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
GB0225799D0
(en)
*
|
2002-11-05 |
2002-12-11 |
Novartis Forschungsstiftung |
Tel/etv6-mediated inhibition of cell proliferation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
AU2003290596B2
(en)
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
JP2006507841A
(en)
*
|
2002-11-14 |
2006-03-09 |
ダーマコン, インコーポレイテッド |
Functional and ultrafunctional siRNA
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20040214198A1
(en)
*
|
2002-11-15 |
2004-10-28 |
University Of Massachusetts |
Allele-targeted RNA interference
|
MXPA05005283A
(en)
*
|
2002-11-21 |
2005-07-25 |
Wyeth Corp |
Methods for diagnosing rcc and other solid tumors.
|
US7365186B2
(en)
*
|
2002-11-22 |
2008-04-29 |
Arborgen, Llc |
Vascular-preferred promoter sequences and uses thereof
|
WO2004047764A2
(en)
*
|
2002-11-22 |
2004-06-10 |
University Of Massachusetts |
Modulation of hiv replication by rna interference
|
US7297779B2
(en)
*
|
2002-11-24 |
2007-11-20 |
Daiichi Pharmaceutical Co., Ltd. |
Colon cancer metastasis inhibitor
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
US7605249B2
(en)
*
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7217807B2
(en)
*
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
US20050048641A1
(en)
*
|
2002-11-26 |
2005-03-03 |
Medtronic, Inc. |
System and method for delivering polynucleotides to the central nervous system
|
BR0316737A
(en)
|
2002-11-27 |
2005-12-13 |
Irm Llc |
Methods and compositions for inducing apoptosis in cancer cells
|
US7297525B2
(en)
*
|
2002-11-27 |
2007-11-20 |
Wyeth |
Composition employing a novel human kinase
|
US20040110698A1
(en)
*
|
2002-12-10 |
2004-06-10 |
Kimron Veterinary Institute |
Oligonucleotides and methods using same for treating cox-ll associated diseases
|
JP2006509504A
(en)
*
|
2002-12-11 |
2006-03-23 |
ユニバーシティー オブ マサチューセッツ |
Method for introducing siRNA into adipocytes
|
EP1636248A4
(en)
|
2002-12-16 |
2006-09-06 |
Halozyme Inc |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7078234B2
(en)
|
2002-12-18 |
2006-07-18 |
Monsanto Technology Llc |
Maize embryo-specific promoter compositions and methods for use thereof
|
AU2003301059A1
(en)
*
|
2002-12-18 |
2004-07-22 |
Wyeth |
Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
|
CN1301263C
(en)
*
|
2002-12-18 |
2007-02-21 |
北京昭衍新药研究中心 |
Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
NZ540730A
(en)
|
2002-12-24 |
2010-09-30 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
EP2078753A3
(en)
|
2002-12-26 |
2010-12-15 |
Syngenta Participations AG |
Cell proliferation-related polypeptides and uses therefor
|
US20040248299A1
(en)
*
|
2002-12-27 |
2004-12-09 |
Sumedha Jayasena |
RNA interference
|
DE602004015064D1
(en)
*
|
2003-01-06 |
2008-08-28 |
Wyeth Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF COLONY CANCER
|
CA2513623A1
(en)
*
|
2003-01-16 |
2004-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for sirna inhibition of icam-1
|
ES2356910T3
(en)
*
|
2003-01-17 |
2011-04-14 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
CONSTRUCTIONS FOR THE INDUCIBLE EXPRESSION OF SMALL INTERFERENCE RNA (ARNS) FOR SELECTED GENETIC SILENCING.
|
JP3792655B2
(en)
*
|
2003-01-20 |
2006-07-05 |
日本電気株式会社 |
Novel oncogene, recombinant protein derived from the oncogene, and uses thereof
|
US20040147027A1
(en)
*
|
2003-01-28 |
2004-07-29 |
Troy Carol M. |
Complex for facilitating delivery of dsRNA into a cell and uses thereof
|
WO2004070062A2
(en)
*
|
2003-02-04 |
2004-08-19 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
US20040248839A1
(en)
*
|
2003-02-05 |
2004-12-09 |
University Of Massachusetts |
RNAi targeting of viruses
|
US7326768B2
(en)
*
|
2003-02-05 |
2008-02-05 |
Juan Saus |
Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20040171118A1
(en)
*
|
2003-02-13 |
2004-09-02 |
City Of Hope |
Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
|
EP1592708A2
(en)
|
2003-02-14 |
2005-11-09 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
PL379983A1
(en)
|
2003-02-19 |
2006-11-27 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
AU2004265550A1
(en)
*
|
2003-02-21 |
2005-02-24 |
The Penn State Research Foundation |
RNA interference compositions and methods
|
US20040261149A1
(en)
*
|
2003-02-24 |
2004-12-23 |
Fauquet Claude M. |
siRNA-mediated inhibition of gene expression in plant cells
|
US20040191818A1
(en)
*
|
2003-02-26 |
2004-09-30 |
O'toole Margot Mary |
Compositions and methods for diagnosing and treating autoimmune diseases
|
EP2311948A1
(en)
|
2003-02-28 |
2011-04-20 |
Onco Therapy Science, Inc. |
RNA-interference for ZNFN3A1-gene as a method for inhibiting cancer cell growth
|
WO2004078995A2
(en)
|
2003-03-04 |
2004-09-16 |
Neurogenetics, Inc. |
Methods of modulating and of identifying agents that modulate intracellular calcium
|
KR20050098954A
(en)
*
|
2003-03-05 |
2005-10-12 |
세네스코 테크놀로지스 인코포레이티드 |
Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
|
CA2517145C
(en)
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
EP1604022A2
(en)
*
|
2003-03-06 |
2005-12-14 |
Oligo Engine, Inc. |
Modulation of gene expression using dna-rna hybrids
|
CA2515340C
(en)
*
|
2003-03-06 |
2016-04-26 |
Diversa Corporation |
Amylases, nucleic acids encoding them and methods for making and using them
|
EP2194133B1
(en)
|
2003-03-06 |
2015-12-02 |
BASF Enzymes LLC |
Amylases, nucleic acids encoding them and methods for making and using them
|
CA2889013C
(en)
|
2003-03-07 |
2018-07-17 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP1601382A4
(en)
*
|
2003-03-13 |
2006-11-22 |
Univ Utah Res Found |
Phospholipid scramblase 3
|
ES2576677T3
(en)
*
|
2003-03-21 |
2016-07-08 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA analogs
|
WO2004087901A2
(en)
|
2003-03-25 |
2004-10-14 |
Wyeth |
Brain-localized protein kinases homologous to homeodomain-interacting protein kinases
|
JP2006522806A
(en)
*
|
2003-03-26 |
2006-10-05 |
マルチセル・イミュノセラピューティクス,インコーポレイテッド |
Selected RNA motifs for inducing cell death and / or apoptosis
|
WO2004087903A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Wyeth |
Novel proteins homologous to kinase suppressor of ras
|
WO2004087878A2
(en)
|
2003-03-28 |
2004-10-14 |
Monsanto Technology, Llc |
Novel plant promoters for use in early seed development
|
WO2004087862A2
(en)
*
|
2003-04-01 |
2004-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Tak1-mediated inhibition of osteogenesis
|
US7781414B2
(en)
|
2003-04-01 |
2010-08-24 |
Intradigm Corporation |
Targets for tumor growth inhibition
|
WO2004090105A2
(en)
*
|
2003-04-02 |
2004-10-21 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
US8158420B2
(en)
|
2003-04-04 |
2012-04-17 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
|
HUE030493T2
(en)
|
2003-04-04 |
2017-05-29 |
Basf Enzymes Llc |
Pectate lyases, Nucleic Acids encoding them and methods for making and using them
|
JP4912873B2
(en)
*
|
2003-04-09 |
2012-04-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
iRNA complex
|
EP1615611B1
(en)
*
|
2003-04-09 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
iRNA CONJUGATES
|
WO2004091515A2
(en)
*
|
2003-04-09 |
2004-10-28 |
Alnylam Pharmaceuticals, Inc. |
iRNA CONJUGATES
|
US20070270360A1
(en)
*
|
2003-04-15 |
2007-11-22 |
Sirna Therapeutics, Inc. |
Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
|
EP1469070A1
(en)
*
|
2003-04-15 |
2004-10-20 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Livin-specific siRNAs for the treatment of therapy-resistant tumors
|
JP2006523464A
(en)
*
|
2003-04-18 |
2006-10-19 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Compositions and methods for siRNA inhibition of angiopoietins 1, 2 and their receptor TIE2
|
IL155561A0
(en)
*
|
2003-04-24 |
2006-12-31 |
Yeda Res & Dev |
Oligonucleotides that block toll-like receptors
|
PL1623228T3
(en)
*
|
2003-04-29 |
2013-04-30 |
Biocrine Ab |
Apociii and the treatment and diagnosis of diabetes
|
EP1622572B1
(en)
|
2003-04-30 |
2017-12-20 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
WO2004098634A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
Protein arginine n-methyltransferase 2 (prmt-2)
|
WO2004104217A2
(en)
*
|
2003-05-08 |
2004-12-02 |
Wyeth |
Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases
|
US8067371B2
(en)
*
|
2003-05-09 |
2011-11-29 |
The Trustees Of Columbia University In The City Of New York |
RAGE G82S-related methods and compositions for treating inflammatory disorders
|
WO2004101756A2
(en)
|
2003-05-09 |
2004-11-25 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2004101788A2
(en)
*
|
2003-05-09 |
2004-11-25 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Small interfering rna libraries and methods of synthesis and use
|
AU2003241409A1
(en)
*
|
2003-05-12 |
2005-01-21 |
Potomac Pharmaceuticals, Inc. |
Gene expression suppression agents
|
CA2525619A1
(en)
*
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
EP1631306A4
(en)
|
2003-05-19 |
2009-08-12 |
Univ Columbia |
Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
|
US20070027099A1
(en)
*
|
2003-05-19 |
2007-02-01 |
Lin Marie C |
Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
|
WO2005001092A2
(en)
*
|
2003-05-20 |
2005-01-06 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
US7618632B2
(en)
*
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
US20050042641A1
(en)
*
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
ATE449842T1
(en)
|
2003-05-28 |
2009-12-15 |
Takeda Pharmaceutical |
ANTI-BAMBI ANTIBODIES OR RNA FOR DIAGNOSIS AND THERAPY OF COLON OR LIVER CANCER
|
WO2004111192A2
(en)
*
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
US8092992B2
(en)
*
|
2003-05-29 |
2012-01-10 |
Salk Institute For Biological Studies |
Transcriptional regulation of gene expression by small double-stranded modulatory RNA
|
JP4505749B2
(en)
|
2003-05-30 |
2010-07-21 |
日本新薬株式会社 |
Oligo double-stranded RNA that suppresses expression of Bcl-2 and pharmaceutical composition containing the same
|
ES2357116T5
(en)
*
|
2003-06-02 |
2021-09-03 |
Univ Massachusetts |
Methods and compositions to improve the efficacy and specificity of FNAi
|
ES2712695T3
(en)
*
|
2003-06-02 |
2019-05-14 |
Univ Massachusetts |
Methods and compositions to control the efficiency of RNA silencing
|
US7750144B2
(en)
*
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
EP1633307A4
(en)
|
2003-06-03 |
2009-06-24 |
Isis Pharmaceuticals Inc |
Modulation of survivin expression
|
CA2527907A1
(en)
*
|
2003-06-03 |
2004-12-09 |
Benitec Australia Limited |
Double-stranded hairpin rnas for rnai
|
AU2004252479A1
(en)
*
|
2003-06-06 |
2005-01-06 |
Arborgen Llc. |
Transcription factors
|
EP1639090A4
(en)
|
2003-06-09 |
2008-04-16 |
Univ Michigan |
Compositions and methods for treating and diagnosing cancer
|
CN1836042A
(en)
|
2003-06-12 |
2006-09-20 |
原子核物理公司 |
Conserved HBV and HCV sequences useful for gene silencing
|
WO2004113573A2
(en)
*
|
2003-06-19 |
2004-12-29 |
The Samuel Roberts Noble Foundation, Inc. |
Methods and compositions for analysis of plant gene function
|
WO2005044976A2
(en)
*
|
2003-06-20 |
2005-05-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
US20080131874A1
(en)
*
|
2003-06-24 |
2008-06-05 |
Amitava Mitra |
Method for efficient post-transcriptional gene silencing using intrinsic direct repeat sequences and utilization thereof in functional genomics
|
EP1636385A4
(en)
*
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20070196334A1
(en)
*
|
2003-06-25 |
2007-08-23 |
Shaharyar Khan |
Modified vectors for organelle transfection
|
WO2005003319A2
(en)
|
2003-07-02 |
2005-01-13 |
Diversa Corporation |
Glucanases, nucleic acids encoding them and methods for making and using them
|
US20050019927A1
(en)
*
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
EP2434019A1
(en)
|
2003-08-01 |
2012-03-28 |
BASF Plant Science GmbH |
Process for the production of fine chemicals
|
JP2007517763A
(en)
*
|
2003-08-01 |
2007-07-05 |
エイアンドジー ファーマスーティカル インコーポレイテッド |
Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
|
US20050026290A1
(en)
*
|
2003-08-01 |
2005-02-03 |
Ciardi Joseph Anthony |
Inhibiting gene expression with dsRNA
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
AU2004263865B2
(en)
|
2003-08-08 |
2007-05-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
WO2005021714A2
(en)
|
2003-08-11 |
2005-03-10 |
Diversa Corporation |
Laccases, nucleic acids encoding them and methods for making and using them
|
EP1654349A4
(en)
|
2003-08-14 |
2008-08-20 |
Exelixis Inc |
Sulfs as modifiers of the beta catenin pathway and methods of use
|
US20050112763A1
(en)
*
|
2003-08-21 |
2005-05-26 |
Cold Spring Harbor Laboratory |
RNAI-based modification of heterochromatin
|
IL157538A0
(en)
|
2003-08-21 |
2004-03-28 |
Bar Ilan Res & Dev Company Ltd |
Plant resistant to cytoplasm-feeding parasites
|
WO2005040388A2
(en)
*
|
2003-08-22 |
2005-05-06 |
Nucleonics Inc. |
Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
|
EP1670924A1
(en)
*
|
2003-08-28 |
2006-06-21 |
Aveo Pharmaceuticals, Inc. |
Tumor-specific expression of reporter genes
|
EP2338995A3
(en)
*
|
2003-08-28 |
2012-01-11 |
Novartis AG |
Interfering RNA duplex having blunt-ends and 3'-modifications
|
WO2005026322A2
(en)
*
|
2003-09-11 |
2005-03-24 |
Clontech Laboratories, Inc. |
siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
EP3760234B1
(en)
*
|
2003-09-12 |
2023-11-01 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
US8680063B2
(en)
*
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
EP1682573B1
(en)
|
2003-09-15 |
2014-01-01 |
Cenix Bioscience GmbH |
The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
|
EP1663300A1
(en)
*
|
2003-09-16 |
2006-06-07 |
Pharmacia Corporation |
Inhibitors of pace4 for the treatment of arthritis
|
AU2004276823A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Merck And Co., Inc |
Synthetic lethal screen using RNA interference
|
US20050282168A1
(en)
*
|
2003-09-29 |
2005-12-22 |
Wyeth |
Cell surface molecules as markers and therapeutic agents against kidney cancers
|
EP1672060A4
(en)
*
|
2003-09-30 |
2006-12-27 |
Takara Bio Inc |
Polypeptide having rnase iii activity
|
US20070218551A1
(en)
*
|
2003-10-02 |
2007-09-20 |
Chuan-Yuan Li |
Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy
|
EP1687410A4
(en)
*
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
Antisense oligonucleotides optimized for kidney targeting
|
US20050120415A1
(en)
*
|
2003-10-09 |
2005-06-02 |
E.I. Du Pont De Nemours And Company |
Gene silencing
|
CA2543789A1
(en)
|
2003-10-23 |
2005-05-06 |
Illumigen Biosciences, Inc. |
Detection of mutations in a gene associated with resistance to viral infection, oas1
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8507277B2
(en)
*
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US8039587B2
(en)
*
|
2003-10-24 |
2011-10-18 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
EP1692262B1
(en)
|
2003-10-27 |
2018-08-15 |
Merck Sharp & Dohme Corp. |
Method of designing sirnas for gene silencing
|
US8012944B2
(en)
*
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
US7553822B2
(en)
*
|
2003-10-30 |
2009-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene
|
WO2005042782A1
(en)
*
|
2003-10-31 |
2005-05-12 |
The Trustees Of Columbia University In The City Of New York |
Methods for reducing seizure-induced neuronal damage
|
US20070083943A1
(en)
*
|
2003-10-31 |
2007-04-12 |
Hannah L C |
Materials and methods for improved sweet corn
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
CA2545182A1
(en)
*
|
2003-11-10 |
2005-05-26 |
University Of Utah Research Foundation |
Improved methods and compositions for rna interference
|
WO2005049838A2
(en)
*
|
2003-11-14 |
2005-06-02 |
Yale University |
Syk-targeted nucleic acid interference
|
US7763592B1
(en)
*
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US7807646B1
(en)
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
CA2546853C
(en)
*
|
2003-11-21 |
2020-04-21 |
Revivicor, Inc. |
Use of interfering rna in the production of transgenic animals
|
US20050166289A1
(en)
*
|
2003-12-01 |
2005-07-28 |
North Carolina State University |
Small interfering RNA (siRNA)-mediated heritable gene manipulation in plants
|
WO2005054438A2
(en)
|
2003-12-01 |
2005-06-16 |
Invitrogen Corporation |
Nucleic acid molecules containing recombination sites and methods of using the same
|
AU2004294824A1
(en)
|
2003-12-03 |
2005-06-16 |
Coda Therapeutics (Nz) Ltd |
Antisense compounds targeted to connexins and methods of use thereof
|
CA2549031A1
(en)
*
|
2003-12-10 |
2005-06-30 |
University Of Utah Research Foundation |
Method for obtaining an enriched population of sirna-expressing cells
|
US20080021205A1
(en)
*
|
2003-12-11 |
2008-01-24 |
Helen Blau |
Methods and Compositions for Use in Preparing Hairpin Rnas
|
JP4753130B2
(en)
*
|
2003-12-12 |
2011-08-24 |
独立行政法人産業技術総合研究所 |
Long interfering double-stranded RNA with reduced interferon response
|
WO2005062937A2
(en)
*
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
US20050164970A1
(en)
*
|
2003-12-22 |
2005-07-28 |
University Of Kansas Medical Center |
Method for treating prostate cancer using siRNA duplex for androgen receptor
|
US20060134787A1
(en)
*
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
FR2872383B1
(en)
*
|
2004-07-02 |
2015-10-16 |
Bayer Cropscience Sa |
METHOD FOR MODIFYING GENE EXPRESSION OF PHYTOPATHOGENIC FUNGI
|
CA2548484C
(en)
*
|
2003-12-23 |
2015-04-21 |
Bayer Cropscience Sa |
Method for modifying gene expression of a phytopathogenic fungus
|
EP1701611B1
(en)
|
2003-12-24 |
2011-05-18 |
G2 Inflammation Pty Ltd |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
|
JP4682152B2
(en)
|
2003-12-31 |
2011-05-11 |
ザ・ペン・ステート・リサーチ・ファンデーション |
Methods for predicting and overcoming resistance to chemotherapy for ovarian cancer and methods for predicting the occurrence of colon cancer
|
WO2005069872A2
(en)
*
|
2004-01-15 |
2005-08-04 |
Washington University |
High throughput pharmaceutical screening using drosophila
|
US20080153764A1
(en)
*
|
2004-01-22 |
2008-06-26 |
The Cbr Institute For Biomedical Research, Inc. |
System and Methods For Short Rna Expression
|
US20050203043A1
(en)
*
|
2004-01-23 |
2005-09-15 |
Dharmacon, Inc. |
Identification of toxic nucleotide sequences
|
JP2007520221A
(en)
|
2004-01-23 |
2007-07-26 |
ニュー・イングランド・バイオラブズ・インコーポレイティッド |
Composition and production method of short double-stranded RNA using mutant RNase
|
WO2005072057A2
(en)
*
|
2004-01-30 |
2005-08-11 |
Quark Biotech, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
EP1713912B1
(en)
*
|
2004-01-30 |
2013-09-18 |
Santaris Pharma A/S |
Modified short interfering rna (modified sirna)
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
ATE447024T1
(en)
*
|
2004-02-06 |
2009-11-15 |
Dharmacon Inc |
STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
|
EP1747284A4
(en)
|
2004-02-06 |
2009-03-11 |
Wyeth Corp |
Diagnosis and therapeutics for cancer
|
US7683237B2
(en)
*
|
2004-02-10 |
2010-03-23 |
Monsanto Technology Llc |
Maize seed with synergistically enhanced lysine content
|
AR047598A1
(en)
|
2004-02-10 |
2006-01-25 |
Monsanto Technology Llc |
TRANSGENIZED CORN SEED WITH GREATER AMINO ACID CONTENT
|
EP1713915B1
(en)
|
2004-02-10 |
2009-12-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA)
|
US7855323B2
(en)
*
|
2004-02-10 |
2010-12-21 |
Monsanto Technology Llc |
Recombinant DNA for gene suppression
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
WO2005079389A2
(en)
|
2004-02-13 |
2005-09-01 |
Monsanto Technology, Llc |
In vivo assembly of transcription units
|
EP1727556A2
(en)
*
|
2004-02-17 |
2006-12-06 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US7622301B2
(en)
*
|
2004-02-24 |
2009-11-24 |
Basf Plant Science Gmbh |
Compositions and methods using RNA interference for control of nematodes
|
WO2005082415A2
(en)
|
2004-02-25 |
2005-09-09 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
|
US20060003956A1
(en)
*
|
2004-03-03 |
2006-01-05 |
Casadome David O |
Materials and methods for the derepression of the E-cadherin promoter
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US7947659B2
(en)
|
2004-03-12 |
2011-05-24 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
AU2005223649A1
(en)
*
|
2004-03-19 |
2005-09-29 |
The Penn State Research Foundation |
Combinatorial methods and compositions for treatment of melanoma
|
US7851452B2
(en)
*
|
2004-03-22 |
2010-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods of use of bcl-6-derived nucleotides to induce apoptosis
|
ATE496142T1
(en)
*
|
2004-03-23 |
2011-02-15 |
Oncotherapy Science Inc |
METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER
|
EP2336778A1
(en)
|
2004-03-24 |
2011-06-22 |
Oncotherapy Science, Inc. |
Compositions and methods for treating lung cancer
|
DE602005023426D1
(en)
*
|
2004-03-25 |
2010-10-21 |
California Inst Of Techn |
Hybridization CHAIN REACTION
|
US20060041961A1
(en)
|
2004-03-25 |
2006-02-23 |
Abad Mark S |
Genes and uses for pant improvement
|
KR101147147B1
(en)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Modified polynucleotides for reducing off-target effects in rna interference
|
ES2671522T3
(en)
|
2004-04-02 |
2018-06-06 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing a disease associated with integrin alpha V beta 5
|
ES2338344T3
(en)
*
|
2004-04-07 |
2010-05-06 |
Rinat Neuroscience Corporation |
PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR.
|
CA2562022C
(en)
|
2004-04-09 |
2016-01-26 |
Monsanto Technology Llc |
Compositions and methods for control of insect infestations in plants
|
WO2005117938A2
(en)
*
|
2004-04-13 |
2005-12-15 |
Regents Of The University Of Minnesota |
Methods of treating ocular conditions
|
US20070031417A2
(en)
*
|
2004-04-14 |
2007-02-08 |
University Of Massachusetts |
Dicer interacting proteins and uses therefor
|
US20050233994A1
(en)
*
|
2004-04-16 |
2005-10-20 |
Ajamete Kaykas |
Methods and vectors for expressing siRNA
|
EP2145957B1
(en)
*
|
2004-04-20 |
2013-12-25 |
Marina Biotech, Inc. |
Compositions for enhancing delivery of double-stranded RNA to regulate gene expression in mammalian cells
|
PL1756280T3
(en)
|
2004-04-22 |
2015-04-30 |
Commw Scient Ind Res Org |
Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
|
WO2005103254A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
|
AU2005238034A1
(en)
|
2004-04-23 |
2005-11-10 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of hairless protein mRNA
|
CN102102106B
(en)
|
2004-04-23 |
2013-05-29 |
塞雷斯公司 |
Methods for modifying plant characteristics
|
US8076304B2
(en)
*
|
2004-04-26 |
2011-12-13 |
The Regents Of The University Of Colorado |
Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions
|
ES2427177T3
(en)
|
2004-04-27 |
2013-10-29 |
Galapagos N.V. |
Methods, agents and tests for the detection of compounds to induce differentiation of undifferentiated mammalian cells to give rise to osteoblasts
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US20060035815A1
(en)
*
|
2004-05-04 |
2006-02-16 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
|
WO2005111246A1
(en)
*
|
2004-05-11 |
2005-11-24 |
Wyeth |
Oligonucleotide arrays to monitor gene expression and methods for making and using same
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20080199960A1
(en)
*
|
2004-05-13 |
2008-08-21 |
Juliano Rudolph L |
Methods for the Delivery of Oligomeric Compounds
|
EP2322660A1
(en)
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
MicroRNAs and uses thereof
|
WO2005111211A2
(en)
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
US8563252B2
(en)
*
|
2004-05-14 |
2013-10-22 |
Rosetta Genomics Ltd. |
Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
US7563885B1
(en)
*
|
2004-05-24 |
2009-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of Tudor-SN expression
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
WO2006033679A2
(en)
*
|
2004-05-25 |
2006-03-30 |
Chimeracore, Inc. |
Self-assembling nanoparticle drug delivery system
|
EP2471924A1
(en)
*
|
2004-05-28 |
2012-07-04 |
Asuragen, INC. |
Methods and compositions involving microRNA
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
WO2005121372A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060003410A1
(en)
*
|
2004-06-10 |
2006-01-05 |
Lee-Ming Chuang |
Prostaglandin reductase
|
WO2006009676A2
(en)
|
2004-06-16 |
2006-01-26 |
Diversa Corporation |
Compositions and methods for enzymatic decolorization of chlorophyll
|
US20060010505A1
(en)
*
|
2004-06-18 |
2006-01-12 |
Washington University |
High throughput cancer pharmaceutical screening using drosophila
|
US20060156421A1
(en)
*
|
2004-06-18 |
2006-07-13 |
Cagan Ross L |
High throughput screening methods for anti-metastatic compounds
|
JP5058792B2
(en)
|
2004-06-21 |
2012-10-24 |
プロティオーム・サイエンシィズ・ピーエルシー |
Screening method
|
US20100098663A2
(en)
|
2004-06-22 |
2010-04-22 |
The Board Of Trustees Of The University Of Illinois |
Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
|
CA2559760A1
(en)
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
US8680062B2
(en)
|
2004-07-06 |
2014-03-25 |
Deliversir Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
EP1784509A2
(en)
*
|
2004-07-20 |
2007-05-16 |
Wyeth a Corporation of the State of Delaware |
Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP2484780A1
(en)
|
2004-07-23 |
2012-08-08 |
The University of North Carolina At Chapel Hill |
Methods and materials for determining pain sensibility and predicting and treating related disorders
|
KR20130019457A
(en)
|
2004-07-26 |
2013-02-26 |
다우 글로벌 테크놀로지스 엘엘씨 |
Process for improved protein expression by strain engineering
|
DE102004036456A1
(en)
*
|
2004-07-28 |
2006-03-23 |
Basf Plant Science Gmbh |
Method for producing transgenic plants with increased pathogen resistance by changing the content and / or the activity of actin-depolymerizing factors
|
US20060075522A1
(en)
|
2004-07-31 |
2006-04-06 |
Jaclyn Cleveland |
Genes and uses for plant improvement
|
EP1781784A2
(en)
|
2004-08-02 |
2007-05-09 |
BASF Plant Science GmbH |
Method for isolation of transcription termination sequences
|
JP5060293B2
(en)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
TAJ in neural function
|
CN101128588A
(en)
|
2004-08-11 |
2008-02-20 |
孟山都技术有限公司 |
Enhanced zein reduction in transgenic corn seed
|
BRPI0514342A2
(en)
*
|
2004-08-13 |
2009-10-06 |
Basf Plant Science Gmbh |
double stranded rna molecule, grouping of double stranded rna molecules, transgenic plant, and methods for controlling a parasitic nematode's infection of a plant and for manufacturing a transgenic plant
|
EA012799B1
(en)
*
|
2004-08-16 |
2009-12-30 |
Кварк Фармасьютикалс, Инк. |
Therapeutic uses of inhibitors of rtp801
|
WO2006017932A1
(en)
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
EP2169072A1
(en)
|
2004-08-23 |
2010-03-31 |
Alnylam Pharmaceuticals, Inc |
Multiple RNA polymerase III promoter expression constructs
|
US20090313712A1
(en)
*
|
2004-08-25 |
2009-12-17 |
Leandro Christmann |
RNA interference and disease resistance in avians
|
US20080222743A1
(en)
*
|
2004-08-25 |
2008-09-11 |
Avigenics, Inc. |
RNA interference and disease resistance in avians
|
US20060046247A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Rapp Jeffrey C |
Protecting avians from pathogens
|
US20060046248A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Avigenics, Inc. |
RNA interference in avians
|
WO2006026738A2
(en)
*
|
2004-08-31 |
2006-03-09 |
Qiagen North American Holdings, Inc. |
Methods and compositions for rna amplification and detection using an rna-dependent rna-polymerase
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US7595433B2
(en)
|
2004-09-14 |
2009-09-29 |
Ceres, Inc. |
Modulations of amino acid and sugar content in plants
|
US20060059585A1
(en)
|
2004-09-14 |
2006-03-16 |
Boris Jankowski |
Modulating plant sugar levels
|
FI20041204A0
(en)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Methods for the utilization of new target genes associated with immune-mediated diseases
|
AU2005290238A1
(en)
|
2004-09-18 |
2006-04-06 |
Department Of Veterans Affairs |
Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
|
ATE487484T1
(en)
|
2004-09-18 |
2010-11-15 |
Univ Maryland |
THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND METHOD OF USE THEREOF
|
US7456338B2
(en)
|
2004-09-22 |
2008-11-25 |
Arborgen Llc |
Modification of plant lignin content
|
US7799906B1
(en)
|
2004-09-22 |
2010-09-21 |
Arborgen, Llc |
Compositions and methods for modulating lignin of a plant
|
US7402428B2
(en)
|
2004-09-22 |
2008-07-22 |
Arborgen, Llc |
Modification of plant lignin content
|
AU2005286427B2
(en)
|
2004-09-24 |
2011-09-15 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance to environmental stress
|
KR101409241B1
(en)
*
|
2004-09-28 |
2014-06-24 |
쿠아크 파마수티칼스 인코퍼레이티드 |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
WO2006039399A2
(en)
*
|
2004-09-29 |
2006-04-13 |
University Of Rochester |
Staufen 1 (stau1) - mediated mrna decay
|
US20090163406A1
(en)
*
|
2004-09-30 |
2009-06-25 |
The Regents Of The University Of California |
Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
|
US8765704B1
(en)
|
2008-02-28 |
2014-07-01 |
Novartis Ag |
Modified small interfering RNA molecules and methods of use
|
CA2581651C
(en)
*
|
2004-10-01 |
2014-12-16 |
Novartis Vaccines And Diagnostics, Inc. |
Cholesterol-labelled modified rna
|
CN101056981A
(en)
*
|
2004-10-04 |
2007-10-17 |
德福根有限公司 |
Method for down-regulating gene expression in fungi
|
US20060247197A1
(en)
|
2004-10-04 |
2006-11-02 |
Van De Craen Marc |
Method for down-regulating gene expression in fungi
|
WO2006070227A2
(en)
*
|
2004-10-04 |
2006-07-06 |
Devgen Nv |
Method for down-regulating gene expression in fungi
|
EP2166098B1
(en)
|
2004-10-05 |
2013-11-06 |
SunGene GmbH |
Constitutive expression cassettes for regulation of plant expression
|
JP2008522585A
(en)
*
|
2004-10-12 |
2008-07-03 |
ザ ロックフェラー ユニバーシティー |
MicroRNA
|
WO2006044531A2
(en)
*
|
2004-10-13 |
2006-04-27 |
Isis Parmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
WO2006044480A2
(en)
|
2004-10-13 |
2006-04-27 |
University Of Georgia Research Foundation, Inc. |
Nematode resistant transgenic plants
|
US7429692B2
(en)
|
2004-10-14 |
2008-09-30 |
Ceres, Inc. |
Sucrose synthase 3 promoter from rice and uses thereof
|
CA2584960A1
(en)
*
|
2004-10-21 |
2006-05-04 |
Charles L. Niblett |
Methods and materials for conferring resistance to pests and pathogens of plants
|
US20060089324A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Sailen Barik |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
WO2006045591A2
(en)
*
|
2004-10-25 |
2006-05-04 |
Devgen N.V. |
Method and constructs for delivering double stranded rna to pest organisms
|
MX2007005069A
(en)
|
2004-10-27 |
2007-06-25 |
Schering Corp |
Compositions and methods for short interfering nucleic acid inhibition of nav1.8.
|
WO2007001448A2
(en)
*
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
PL2302055T3
(en)
|
2004-11-12 |
2015-02-27 |
Asuragen Inc |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
EP1812016A4
(en)
*
|
2004-11-17 |
2010-07-14 |
Univ Maryland |
HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
|
ES2343193T3
(en)
*
|
2004-11-19 |
2010-07-26 |
Miyagi Ken |
MEDICINAL COMPOSITION TO TREAT CANCER OR DIABETES.
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US20060166234A1
(en)
*
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
EP1662000B1
(en)
|
2004-11-25 |
2011-03-30 |
SunGene GmbH |
Expression cassettes for guard cell-preferential expression in plants
|
WO2006060454A2
(en)
*
|
2004-12-02 |
2006-06-08 |
B-Bridge International, Inc. |
Methods of designing small interfering rnas, antisense polynucleotides, and other hybridizing polynucleotides
|
EP1666599A3
(en)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
|
US9758790B2
(en)
|
2004-12-08 |
2017-09-12 |
Ceres, Inc. |
Modulating the level of components within plants
|
WO2006062971A2
(en)
|
2004-12-08 |
2006-06-15 |
Ceres Inc. |
Modulating plant carbon levels
|
EP2072620B1
(en)
|
2004-12-08 |
2013-05-08 |
SunGene GmbH |
Expression casstettes for vascular tissue-preferential expression in plants
|
EP1669456A3
(en)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for meristem-preferential expression in plants
|
WO2006065552A2
(en)
|
2004-12-16 |
2006-06-22 |
Ceres Inc. |
Modulating plant nitrogen levels
|
MX2007007040A
(en)
|
2004-12-17 |
2008-10-24 |
Metanomics Gmbh |
Process for the control of production of fine chemicals.
|
US8404927B2
(en)
*
|
2004-12-21 |
2013-03-26 |
Monsanto Technology Llc |
Double-stranded RNA stabilized in planta
|
US20060200878A1
(en)
|
2004-12-21 |
2006-09-07 |
Linda Lutfiyya |
Recombinant DNA constructs and methods for controlling gene expression
|
NZ556158A
(en)
*
|
2004-12-22 |
2010-04-30 |
Auckland Uniservices Ltd |
Trefoil factors and methods of treating proliferation disorders using same
|
JP2008525029A
(en)
|
2004-12-22 |
2008-07-17 |
ニュークレオニクス・インコーポレイテッド |
HBV and HCV conserved sequences useful for gene silencing
|
US7335760B2
(en)
|
2004-12-22 |
2008-02-26 |
Ceres, Inc. |
Nucleic acid sequences encoding zinc finger proteins
|
TWI401316B
(en)
*
|
2004-12-23 |
2013-07-11 |
Alcon Inc |
Rnai inhibition of serum amyloid a for treatment of glaucoma
|
TWI386225B
(en)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
Rnai inhibition of ctgf for treatment of ocular disorders
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
EP2003205B1
(en)
|
2004-12-28 |
2013-05-01 |
Pioneer Hi-Bred International, Inc. |
Improved grain quality through altered expression of seed proteins
|
US8252742B2
(en)
|
2004-12-30 |
2012-08-28 |
Hill's Pet Nutrition, Inc. |
Methods for enhancing the quality of life of a senior animal
|
BRPI0519690A2
(en)
*
|
2004-12-30 |
2009-03-03 |
Todd M Hauser |
compositions and methods for modulating gene expression using self-protected oligonucleotides
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
CA2594334A1
(en)
|
2005-01-07 |
2006-07-13 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of rsv and therapeutic uses thereof
|
DK1841793T3
(en)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110 antibody compositions and methods for their use
|
EP3059306A1
(en)
|
2005-01-12 |
2016-08-24 |
Monsanto Technology LLC |
Genes and uses for plant improvement
|
DE602006013788D1
(en)
|
2005-01-13 |
2010-06-02 |
Du Pont |
CYCLO-1 GENE FROM MAIZE AND PROMOTER
|
EP1841870B1
(en)
|
2005-01-14 |
2013-09-04 |
University Of Guelph |
Nitrogen-regulated sugar sensing gene and protein and modulation thereof
|
WO2006113679A2
(en)
*
|
2005-04-15 |
2006-10-26 |
Board Of Regents, The University Of Texas System |
Delivery of sirna by neutral lipid compositions
|
US7718625B2
(en)
*
|
2005-01-27 |
2010-05-18 |
University Of South Florida |
Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
|
TW200639252A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
EP2662088A3
(en)
*
|
2005-02-03 |
2014-02-19 |
Coda Therapeutics Limited |
Anti-connexin compounds and uses thereof
|
CN103131697A
(en)
|
2005-02-09 |
2013-06-05 |
巴斯福植物科学有限公司 |
Expression cassettes for regulation of expression in monocotyledonous plants
|
EP1848743A2
(en)
*
|
2005-02-14 |
2007-10-31 |
Wyeth |
Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
|
JP2008529536A
(en)
|
2005-02-14 |
2008-08-07 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
Methods and reagents for treating and diagnosing age-related macular degeneration
|
EP1849011A2
(en)
*
|
2005-02-14 |
2007-10-31 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Use of il-17f in diagnosis and therapy of airway inflammation
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
US20090031440A1
(en)
|
2005-02-26 |
2009-01-29 |
Basf Plant Science Gmbh |
Expression Cassettes for Seed-Preferential Expression in Plants
|
US7727721B2
(en)
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
CN102925479A
(en)
|
2005-03-08 |
2013-02-13 |
巴斯福植物科学有限公司 |
Expression enhancing intron sequences
|
BRPI0607985A2
(en)
|
2005-03-10 |
2009-10-27 |
Genentech Inc |
dscr1 modulator, treatment methods, side effect amelioration method and tumor growth inhibition method
|
WO2006099207A2
(en)
|
2005-03-10 |
2006-09-21 |
Diversa Corporation |
Lyase enzymes, nucleic acids encoding them and methods for making and using them
|
DE202005004135U1
(en)
*
|
2005-03-11 |
2005-05-19 |
Klocke Verpackungs-Service Gmbh |
Multi-component packaging with applicator
|
US7947660B2
(en)
|
2005-03-11 |
2011-05-24 |
Alcon, Inc. |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
WO2006130201A1
(en)
*
|
2005-03-14 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
DE102005011648A1
(en)
*
|
2005-03-14 |
2006-09-21 |
IPK-Institut für Pflanzengenetik und Kulturpflanzenforschung |
A method of increasing fungal resistance in transgenic plants by host-induced suppression of gene expression in fungal pathogens
|
AU2006227965B2
(en)
|
2005-03-15 |
2013-01-31 |
Bp Corporation North America Inc. |
Cellulases, nucleic acids encoding them and methods for making and using them
|
WO2006099875A1
(en)
|
2005-03-23 |
2006-09-28 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
JP4131271B2
(en)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
Information processing apparatus and method, and program
|
RU2533804C2
(en)
*
|
2005-03-31 |
2014-11-20 |
Ронен КАХАНА |
Producing poultry and other animals resistant to viral diseases
|
DK1866414T3
(en)
|
2005-03-31 |
2012-04-23 |
Calando Pharmaceuticals Inc |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
US20060234973A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Kevin Fitzgerald |
Transcription factor RNA interference reagents and methods of use thereof
|
US7985852B2
(en)
|
2005-04-15 |
2011-07-26 |
National University Corporation Tottori University |
hTERT gene expression regulatory gene
|
WO2006112879A2
(en)
*
|
2005-04-15 |
2006-10-26 |
The Trustees Of The University Of Pennsylvania |
Hunk, a snf1-related kinase essential for mammary tumor metastasis
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
BRPI0608829A2
(en)
|
2005-04-19 |
2011-03-15 |
Basf Plant Science Gmbh |
method for transgenic expression with enhanced specificity in a plant, use of a chimeric nucleic acid construct, chimeric ribonucleotide sequence, expression construct, expression vector, nonhuman organism or transformed cell, transformed seed, and pharmaceutical preparation
|
ATE552343T1
(en)
|
2005-04-19 |
2012-04-15 |
Basf Plant Science Gmbh |
ENDOSPERM-SPECIFIC EXPRESSION AND/OR EXPRESSION IN GERMINATING EMBRYOS OF MONOCOTYLEDONE PLANTS
|
WO2006120197A2
(en)
|
2005-05-10 |
2006-11-16 |
Basf Plant Science Gmbh |
Expression cassettes for seed-preferential expression in plants
|
WO2006124699A2
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8669236B2
(en)
*
|
2005-05-12 |
2014-03-11 |
The General Hospital Corporation |
Biotinylated compositions
|
FR2885808B1
(en)
|
2005-05-19 |
2007-07-06 |
Oreal |
VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND TOPICAL USE.
|
WO2007001684A2
(en)
*
|
2005-05-19 |
2007-01-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
|
CA2610265A1
(en)
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
WO2006129204A2
(en)
|
2005-05-31 |
2006-12-07 |
Devgen Nv |
Rnai for control of insects and arachnids
|
CN101213300B
(en)
*
|
2005-06-01 |
2013-01-23 |
聚加转染股份有限公司 |
Oligonucleotides for RNA interference and biological applications thereof
|
WO2006133287A2
(en)
*
|
2005-06-06 |
2006-12-14 |
Wyeth |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
WO2006132606A1
(en)
*
|
2005-06-09 |
2006-12-14 |
Agency For Science, Technology And Research |
Hepatic stellate cell specific promoter and uses thereof
|
US20070299029A1
(en)
*
|
2005-06-09 |
2007-12-27 |
Agency For Science, Technology And Research |
Hepatic stellate cell specific promoter and uses thereof
|
US20070014776A1
(en)
*
|
2005-06-09 |
2007-01-18 |
Gimeno Ruth E |
Identification of adiponutrin-related proteins as esterases and methods of use for the same
|
US8124111B2
(en)
*
|
2005-06-10 |
2012-02-28 |
Children's Hospital & Research Center At Oakland |
Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity
|
WO2006131925A2
(en)
*
|
2005-06-10 |
2006-12-14 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
WO2006138275A2
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2267390B1
(en)
*
|
2005-06-16 |
2008-03-16 |
Universidad Politecnica De Valencia |
INSULATION AND CHARACTERIZATION OF MUTANT CSB3-1 OF THALIAN ARABIDOPSIS, AND ITS USE AS A REGULATOR OF THE RESISTANCE IN PLANTS TO DISEASES PRODUCED BY BIOTROPHIC PATHOGENS.
|
ATE495265T1
(en)
|
2005-06-23 |
2011-01-15 |
Basf Plant Science Gmbh |
IMPROVED METHODS FOR PRODUCING STABLE TRANSFORMED AND FERTILIZED COLORED CORN PLANTS
|
US20080280843A1
(en)
|
2006-05-24 |
2008-11-13 |
Van Bilsen Paul |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
JP2009500019A
(en)
*
|
2005-07-01 |
2009-01-08 |
プロメガ・コーポレーション |
Suspended particle network for the purification of biomolecules, and the use of buoyant particles or buoyant particle networks for the purification of biomolecules
|
CA2614531C
(en)
*
|
2005-07-07 |
2015-06-16 |
Avraham Hochberg |
Nucleic acid agents for downregulating h19, and methods of using same
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
CN101273141B
(en)
*
|
2005-07-26 |
2013-03-27 |
桑格摩生物科学股份有限公司 |
Targeted integration and expression of exogenous nucleic acid sequences
|
JP2009502112A
(en)
*
|
2005-07-28 |
2009-01-29 |
オンコセラピー・サイエンス株式会社 |
Methods for diagnosing and treating renal cell carcinoma
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
AU2006279325B2
(en)
|
2005-08-18 |
2013-06-27 |
Accelalox, Inc. |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
US20070161591A1
(en)
|
2005-08-18 |
2007-07-12 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
TW200801201A
(en)
*
|
2005-08-23 |
2008-01-01 |
Illumigen Biosciences Inc |
Detection of mutations in a gene associated with resistance to viral infection, OAS2 or OAS3
|
WO2007025231A2
(en)
*
|
2005-08-26 |
2007-03-01 |
The Trustees Of The University Of Pennsylvania |
Methods using snail transcriptional repressor
|
WO2007028147A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin |
Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
|
CA2620803A1
(en)
|
2005-09-01 |
2007-03-08 |
Suntory Limited |
Tryptophan transporter gene and use thereof
|
US20090018097A1
(en)
*
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
AU2006287553A1
(en)
|
2005-09-08 |
2007-03-15 |
Chromatin, Inc. |
Plants modified with mini-chromosomes
|
WO2007033187A2
(en)
|
2005-09-12 |
2007-03-22 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
EP1764091B1
(en)
|
2005-09-15 |
2017-08-30 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
PT2295584E
(en)
|
2005-09-16 |
2015-09-22 |
Devgen Nv |
Transgenic plant-based methods for plant pests using rnai
|
TWI390037B
(en)
|
2005-09-16 |
2013-03-21 |
Monsanto Technology Llc |
Methods for genetic control of insect infestations in plants and compositions thereof
|
EP1931789B1
(en)
|
2005-09-20 |
2016-05-04 |
BASF Plant Science GmbH |
Methods for controlling gene expression using ta-siran
|
ES2374450T3
(en)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN.
|
WO2007038492A2
(en)
|
2005-09-26 |
2007-04-05 |
The Trustees Of Columbia University In The City Of New York |
Side population cells in cardiac repair
|
JP2009510102A
(en)
*
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
Immunomodulatory compositions and uses thereof
|
US20070079396A1
(en)
*
|
2005-10-03 |
2007-04-05 |
Malvar Thomas M |
Transgenic plant seed with increased lysine
|
EP1931806B1
(en)
|
2005-10-07 |
2011-10-05 |
California Institute Of Technology |
Pkr activation via hybridization chain reaction
|
US8093369B2
(en)
*
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
WO2007047706A2
(en)
|
2005-10-17 |
2007-04-26 |
Children's Hospital |
Methods and compositions for regulating gene expression
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
CA2626304C
(en)
|
2005-10-20 |
2015-07-14 |
Commonwealth Scientific And Industrial Research Organisation |
Cereals with altered dormancy
|
SI1945665T1
(en)
*
|
2005-10-21 |
2012-03-30 |
Genzyme Corp |
Antibody-based therapeutics with enhanced adcc activity
|
NZ568385A
(en)
|
2005-10-21 |
2012-07-27 |
Univ California |
C-kit oncogene mutations in melanoma
|
CA2627025A1
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
US7723314B1
(en)
|
2005-10-28 |
2010-05-25 |
Transderm, Inc. |
Methods and compositions for treating pachyonychia congenita
|
AU2006308847C1
(en)
*
|
2005-10-31 |
2012-05-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
EP1961065A4
(en)
|
2005-10-31 |
2009-11-11 |
Oncomed Pharm Inc |
Compositions and methods for diagnosing and treating cancer
|
US7582745B2
(en)
|
2005-11-04 |
2009-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Nav1.8 gene
|
EP1948806A2
(en)
|
2005-11-08 |
2008-07-30 |
BASF Plant Science GmbH |
Use of armadillo repeat (arm1) polynucleotides for obtaining pathogen resistance in plants
|
AU2006311730B2
(en)
|
2005-11-09 |
2010-12-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
|
CN100447243C
(en)
*
|
2005-11-15 |
2008-12-31 |
中国人民解放军第四军医大学 |
HBV specificity interference target point gene and its siRNA and application in anti HBV infecting thereof
|
DK2641970T3
(en)
|
2005-11-17 |
2015-02-02 |
Univ Texas |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
US8603991B2
(en)
*
|
2005-11-18 |
2013-12-10 |
Gradalis, Inc. |
Individualized cancer therapy
|
US8916530B2
(en)
*
|
2005-11-18 |
2014-12-23 |
Gradalis, Inc. |
Individualized cancer therapy
|
WO2007060240A2
(en)
*
|
2005-11-25 |
2007-05-31 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors
|
WO2007064759A2
(en)
*
|
2005-11-29 |
2007-06-07 |
The Scripps Research Institute |
Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
|
JP4737531B2
(en)
|
2005-12-05 |
2011-08-03 |
サントリーホールディングス株式会社 |
Method for producing ceramide using transformed yeast
|
US20090317802A1
(en)
*
|
2005-12-09 |
2009-12-24 |
Bhatia Sangeeta N |
Compositions and Methods to Monitor RNA Delivery to Cells
|
CA2632405A1
(en)
|
2005-12-09 |
2007-06-14 |
Basf Plant Science Gmbh |
Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
|
US8030034B2
(en)
|
2005-12-09 |
2011-10-04 |
Promega Corporation |
Nucleic acid purification with a binding matrix
|
WO2007070682A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
EP2330202A3
(en)
|
2006-01-06 |
2011-09-14 |
University Of Georgia Research Foundation, Inc. |
Cyst nematode resistant transgenic plants
|
EP1979484B1
(en)
*
|
2006-01-12 |
2014-03-19 |
BASF Plant Science GmbH |
Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
|
WO2007080126A2
(en)
|
2006-01-12 |
2007-07-19 |
Devgen N.V. |
Dsrna as insect control agent
|
US8906876B2
(en)
|
2006-01-12 |
2014-12-09 |
Devgen Nv |
Methods for controlling pests using RNAi
|
EP2374462A3
(en)
|
2006-01-12 |
2011-12-14 |
deVGen N.V. |
Methods for controlling pests using RNAi
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
CN100562342C
(en)
*
|
2006-01-17 |
2009-11-25 |
奥林格斯技术有限公司 |
The oligonucleotide drug of control influenza infection
|
KR20080094064A
(en)
*
|
2006-01-17 |
2008-10-22 |
바이오렉스 쎄라퓨틱스, 인코포레이티드 |
Compositions and methods for humanization and optimization of n-glycans in plants
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
NL2000439C2
(en)
*
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutic applications of inhibitors of RTP801.
|
US8222482B2
(en)
|
2006-01-26 |
2012-07-17 |
Ceres, Inc. |
Modulating plant oil levels
|
DK1981902T3
(en)
|
2006-01-27 |
2015-10-05 |
Biogen Ma Inc |
Nogo Receptor Antagonists
|
WO2007085485A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
EP1987142A4
(en)
|
2006-02-02 |
2009-07-15 |
Verenium Corp |
Esterases and related nucleic acids and methods
|
US20080022423A1
(en)
*
|
2006-02-03 |
2008-01-24 |
Monsanto Technology Llc |
IN PLANTA RNAi CONTROL OF FUNGI
|
ES2479090T3
(en)
|
2006-02-10 |
2014-07-23 |
Monsanto Technology, Llc |
Identification and use of target genes for the control of plant parasitic nematodes
|
EP2450439B1
(en)
|
2006-02-10 |
2013-11-27 |
Verenium Corporation |
Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
|
EP1984511A2
(en)
|
2006-02-13 |
2008-10-29 |
Monsanto Technology LLP |
Selecting and stabilizing dsrna constructs
|
CN101421406B
(en)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
For producing nucleic acid construct and the method that the seed oil of change forms
|
CA2946924A1
(en)
|
2006-02-14 |
2007-08-23 |
Bp Corporation North America Inc. |
Xylanases, nucleic acids encoding them and methods for making and using them
|
US20070293657A1
(en)
*
|
2006-02-17 |
2007-12-20 |
Nastech Pharmaceutical Company Inc. |
Complexes and methods of forming complexes of ribonucleic acids and peptides
|
WO2007097097A1
(en)
|
2006-02-24 |
2007-08-30 |
Suntory Limited |
Ammonia transporter gene and use thereof
|
JP2009165352A
(en)
*
|
2006-02-24 |
2009-07-30 |
Suntory Liquors Ltd |
ACYL-CoA:ETHANOL O-ACYLTRANSFERASE/ESTERASE GENE AND USE THEREOF
|
US20090074913A1
(en)
|
2006-02-24 |
2009-03-19 |
Suntory Limited |
Gene Encoding Protein Responsible for Flocculation Property of Yeast and Use Thereof
|
WO2007120989A2
(en)
|
2006-02-24 |
2007-10-25 |
Ceres, Inc. |
Shade regulatory regions
|
US20090061427A1
(en)
|
2006-02-24 |
2009-03-05 |
Yoshihiro Nakao |
Gene Encoding Protein Responsible for Flocculation Property of Yeast and Use Thereof
|
JPWO2007097093A1
(en)
*
|
2006-02-27 |
2009-07-09 |
サントリーホールディングス株式会社 |
Branched amino acid transporter gene and use thereof
|
JPWO2007097095A1
(en)
*
|
2006-02-27 |
2009-07-09 |
サントリーホールディングス株式会社 |
Aromatic amino acid transporter gene and use thereof
|
JP2009528845A
(en)
*
|
2006-03-08 |
2009-08-13 |
プロメガ・コーポレーション |
Purification method of low molecular weight RNA
|
US7910566B2
(en)
*
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
WO2007104570A2
(en)
*
|
2006-03-16 |
2007-09-20 |
Devgen N.V. |
Nematode control
|
ES2368608T3
(en)
|
2006-03-20 |
2011-11-18 |
Novozymes, Inc. |
POLYPEPTIDES WITH ENDOGLUCANASE AND POLYNUCLEOTIDE ACTIVITY CODIFYING THE POLYPEPTIDES.
|
AU2007229161B2
(en)
*
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
FR2898908A1
(en)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
|
US8063267B2
(en)
|
2006-03-30 |
2011-11-22 |
Novozymes, Inc. |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
WO2007123777A2
(en)
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
KR101462874B1
(en)
|
2006-03-31 |
2014-11-18 |
알닐람 파마슈티칼스 인코포레이티드 |
DsRNA for inhibiting expression of Eg5 gene
|
JP2009534309A
(en)
|
2006-03-31 |
2009-09-24 |
マサチューセッツ インスティテュート オブ テクノロジー |
System for targeted delivery of therapeutic agents
|
EP2090662A3
(en)
|
2006-04-05 |
2012-10-31 |
Metanomics GmbH |
Process for the production of a fine chemical
|
US8524454B2
(en)
|
2006-04-07 |
2013-09-03 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
DE602007005366D1
(en)
*
|
2006-04-07 |
2010-04-29 |
Chimeros Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF B-CELL MALIGNOMES
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US7625874B2
(en)
*
|
2006-04-11 |
2009-12-01 |
The Regents Of The University Of California |
Compositions and methods for treating diseases associated with T-box and N-Myc
|
AU2007238636A1
(en)
|
2006-04-13 |
2007-10-25 |
Novartis Vaccines & Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancer
|
US20100055116A1
(en)
*
|
2006-04-13 |
2010-03-04 |
Liou Hsiou-Chi |
Methods and Compositions for Targeting c-Rel
|
CN101484578A
(en)
*
|
2006-04-19 |
2009-07-15 |
惠氏公司 |
Short interfering rna duplexes targeting an ires sequence and uses therefor
|
US20080070268A1
(en)
*
|
2006-04-21 |
2008-03-20 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and the uses thereof
|
CA2656990A1
(en)
*
|
2006-04-28 |
2007-11-08 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
GB0608838D0
(en)
*
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US20070281900A1
(en)
*
|
2006-05-05 |
2007-12-06 |
Nastech Pharmaceutical Company Inc. |
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
|
SI2032134T1
(en)
|
2006-05-09 |
2015-10-30 |
Genzyme Corporation |
Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
|
EP2021507A4
(en)
|
2006-05-11 |
2009-10-28 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
GB0609498D0
(en)
*
|
2006-05-12 |
2006-06-21 |
Oncomethylome Sciences S A |
Novel methylation marker
|
JP5630998B2
(en)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
Polymers for functional particles
|
CA2652328A1
(en)
|
2006-05-15 |
2007-11-22 |
Takeda Pharmaceutical Company Limited |
Prophylactic and therapeutic agent for cancer
|
CA2843961A1
(en)
|
2006-05-16 |
2007-11-29 |
Monsanto Technology Llc |
Use of non-agrobacterium bacterial species for plant transformation
|
US20070286863A1
(en)
*
|
2006-05-17 |
2007-12-13 |
Christopher Sinal |
CMKLR regulation of adipogenesis and adipocyte metabolic function
|
WO2007137117A2
(en)
*
|
2006-05-17 |
2007-11-29 |
Massachusetts Institute Of Technology |
Aptamer-directed drug delivery
|
US20070269892A1
(en)
*
|
2006-05-18 |
2007-11-22 |
Nastech Pharmaceutical Company Inc. |
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
BRPI0712034A2
(en)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
aha rnai modulation and therapeutic uses thereof
|
ES2413804T3
(en)
*
|
2006-05-19 |
2013-07-17 |
Alcon Research, Ltd. |
RNAi-mediated inhibition of states related to tumor necrosis factor-alpha
|
EP2584051B1
(en)
|
2006-05-22 |
2014-07-16 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expressions of IKK-B gene
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
WO2007139972A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Wyeth |
Expression of the cysteine protease legumain in vascular and inflammatory diseases
|
CA2654165A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US9315818B2
(en)
|
2006-06-07 |
2016-04-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Plant expression constructs and methods of utilizing same
|
EP2026843A4
(en)
*
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
Therapeutic uses of inhibitors of rtp801l
|
WO2007146953A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
Compositions and methods for sirna inhibition of angiogenesis
|
JP5554564B2
(en)
|
2006-06-13 |
2014-07-23 |
ザ ロックフェラー ユニヴァーシティ |
Novel therapeutic and diagnostic products and methods
|
WO2007147067A2
(en)
*
|
2006-06-14 |
2007-12-21 |
Rosetta Inpharmatics Llc |
Methods and compositions for regulating cell cycle progression
|
US8227437B2
(en)
*
|
2006-06-22 |
2012-07-24 |
Tai June Yoo |
Restoration of hearing loss
|
US9381477B2
(en)
|
2006-06-23 |
2016-07-05 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP2010500867A
(en)
|
2006-06-30 |
2010-01-14 |
ロゼッタ ジノミクス リミテッド |
Nucleic acid detection method
|
US8097596B2
(en)
*
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
US20130191941A1
(en)
|
2006-07-05 |
2013-07-25 |
Shing Kwok |
Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants
|
WO2008005631A2
(en)
|
2006-07-07 |
2008-01-10 |
Washington State University |
Genes encoding chavicol/eugenol synthase from the creosote bush larrea tridentata
|
EP2037737B1
(en)
|
2006-07-11 |
2014-04-02 |
University Of Medicine And Dentistry Of New Jersey |
Cell membrane repair proteins, nucleic acids encoding the same and associated methods of use
|
US8536429B2
(en)
|
2006-07-12 |
2013-09-17 |
Commonwealth Scientific And Industrial Research Organisation |
Polynucleotides encoding a NAX2 polypeptide and methods for enhancing salinity tolerance in plants
|
EP2046807B1
(en)
|
2006-07-13 |
2012-03-28 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
CA2658786A1
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
PL380335A1
(en)
*
|
2006-07-31 |
2008-02-04 |
Instytut Chemii Bioorganicznej Pan W Poznaniu |
Sequence of double-stranded ATN-RNA, intervention using interference RNA (iRnAi) as well as application of sequence of double-stranded ATN-RNA in brain tumour treatment
|
MX369001B
(en)
|
2006-08-04 |
2019-10-24 |
Basf Enzymes Llc |
Glucanases, nucleic acids encoding them and methods for making and using them.
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
CA2660485C
(en)
|
2006-08-11 |
2016-04-12 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease-mediated homologous recombination
|
US9580515B2
(en)
|
2006-08-21 |
2017-02-28 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Neukinase, a downstream protein of neuregulin
|
WO2008025711A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Basf Plant Science Gmbh |
Method for increasing resistance to pathogens in transgenic plants
|
EP2390337B1
(en)
|
2006-08-31 |
2017-10-11 |
Monsanto Technology LLC |
Plant transformation without selection
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
US20080261216A1
(en)
*
|
2006-09-08 |
2008-10-23 |
The Regents Of The University Of Michigan |
HERV Group II Viruses In Lymphoma And Cancer
|
EP2062597A4
(en)
|
2006-09-15 |
2010-03-03 |
Univ Tokai |
Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
|
US7737266B2
(en)
|
2006-09-18 |
2010-06-15 |
Board Of Regents, The University Of Texas System |
RNAi modulation of SCAP and therapeutics uses thereof
|
EP2145001A2
(en)
*
|
2006-09-19 |
2010-01-20 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
CA2663878A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
EA015591B1
(en)
|
2006-09-21 |
2011-10-31 |
Верениум Корпорейшн |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
US8877478B2
(en)
|
2006-09-21 |
2014-11-04 |
Verenium Corporation |
Phytases, nucleic acids encoding them and methods for making and using them
|
WO2008036841A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
WO2008040787A2
(en)
|
2006-10-06 |
2008-04-10 |
Basf Plant Science Gmbh |
Processes for producing polyunsaturated fatty acids in transgenic organisms
|
EP3378953A1
(en)
|
2006-10-12 |
2018-09-26 |
Monsanto Technology LLC |
Plant micrornas and methods of use thereof
|
WO2008043575A2
(en)
|
2006-10-13 |
2008-04-17 |
Novosom Ag |
Improvements in or relating to amphoteric liposomes
|
EP2076600A1
(en)
|
2006-10-18 |
2009-07-08 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
JP2010507387A
(en)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Novel siRNA and method of using the same
|
US9532980B2
(en)
|
2006-10-25 |
2017-01-03 |
The Rockefeller University |
Methods for the treatment of A-β related disorders and compositions therefor
|
US8362322B2
(en)
|
2006-10-27 |
2013-01-29 |
Ceres, Inc. |
Modulating lignin in plants
|
US9279127B2
(en)
*
|
2006-11-01 |
2016-03-08 |
The Medical Research Fund At The Tel-Aviv Sourasky Medical Center |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
EP2548438B1
(en)
|
2006-11-08 |
2015-08-05 |
Veritas Bio, LLC |
In vivo delivery of double stranded RNA to a target cell
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
US8758998B2
(en)
|
2006-11-09 |
2014-06-24 |
Gradalis, Inc. |
Construction of bifunctional short hairpin RNA
|
US20100247552A1
(en)
|
2006-11-10 |
2010-09-30 |
Massachusetts Institute Of Technology |
Pak modulators
|
EP2091557A2
(en)
|
2006-11-15 |
2009-08-26 |
Coda Therapeutics, INC. |
Improved methods and compositions for wound healing
|
WO2008147456A2
(en)
*
|
2006-11-20 |
2008-12-04 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
US8222388B2
(en)
|
2006-11-22 |
2012-07-17 |
Ceres, Inc. |
Broadly expressing regulatory regions
|
US20080199475A1
(en)
|
2006-11-27 |
2008-08-21 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
EP2962697A1
(en)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2099818A2
(en)
|
2006-11-29 |
2009-09-16 |
Novozymes Inc. |
Bacillus licheniformis chromosome
|
CN103255114B
(en)
|
2006-11-29 |
2015-03-25 |
诺维信股份有限公司 |
Methods of improving the introduction of DNA into bacterial cells
|
CN101195821A
(en)
*
|
2006-12-04 |
2008-06-11 |
中国科学院上海生命科学研究院 |
Method for improving insect resistance of plant by using RNAi technique
|
WO2009024834A2
(en)
*
|
2006-12-05 |
2009-02-26 |
Rosetta Genomics Ltd |
Nucleic acids involved in viral infection
|
CN101627121A
(en)
*
|
2006-12-08 |
2010-01-13 |
奥斯瑞根公司 |
As the miRNA regulatory gene and the path for the treatment of the target of intervening
|
WO2008067840A1
(en)
|
2006-12-08 |
2008-06-12 |
Swetree Technologies Ab |
Plants having improved growth characteristics and method for making the same
|
AU2007333109A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro RNAs
|
US20090093551A1
(en)
*
|
2006-12-08 |
2009-04-09 |
Bhatia Sangeeta N |
Remotely triggered release from heatable surfaces
|
AU2007333107A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
miR-21 regulated genes and pathways as targets for therapeutic intervention
|
EP3070169B1
(en)
|
2006-12-14 |
2018-05-09 |
Dow AgroSciences LLC |
Optimized non-canonical zinc finger proteins
|
DK2069490T4
(en)
|
2006-12-21 |
2018-04-23 |
Syngenta Participations Ag |
Amylases and Glucoamylases, Nucleic Acids Encoding Them, and Methods of Preparation and Use thereof
|
CN101553503B
(en)
*
|
2006-12-22 |
2012-11-07 |
弗·哈夫曼-拉罗切有限公司 |
SHRNA-mediated inhibition of expression of alpha-1,6-fucosyltransferase
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2111224B1
(en)
|
2007-01-12 |
2016-07-13 |
University of Maryland, Baltimore |
Targeting ncca-atp channel for organ protection following ischemic episode
|
AU2008206975B2
(en)
|
2007-01-15 |
2013-05-02 |
Basf Plant Science Gmbh |
Use of subtilisin (RNR9) polynucleotides for achieving a pathogen resistance in plants
|
WO2008087642A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Nucleic acid constructs and methods for specific silencing of h19
|
US20100204300A1
(en)
*
|
2007-01-17 |
2010-08-12 |
Stephen Mark Tompkins |
Anti-viral methods and compositions
|
US8148147B2
(en)
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
EP2124967A4
(en)
*
|
2007-01-26 |
2011-01-05 |
Rosetta Genomics Ltd |
Compositions and methods for treating hematopoietic malignancies
|
BRPI0806436A2
(en)
|
2007-01-26 |
2011-09-06 |
Univ Lousville Res Foundation Inc |
modification of exosomal components for use as a vaccine
|
WO2008094937A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Joslin Diabetes Center, Inc. |
Methods of modulating angiogenesis
|
BRPI0807132A2
(en)
|
2007-01-30 |
2018-12-04 |
Syngenta Participations Ag |
enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof
|
WO2008097197A1
(en)
|
2007-02-05 |
2008-08-14 |
National University Of Singapore |
Putative cytokinin receptor and methods for use thereof
|
MX2009007608A
(en)
|
2007-02-06 |
2009-07-27 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference for control of nematodes.
|
WO2008095910A1
(en)
|
2007-02-08 |
2008-08-14 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference of opr3-like gene for control of nematodes
|
WO2008098165A2
(en)
*
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
ES2373614T3
(en)
|
2007-02-09 |
2012-02-07 |
Basf Plant Science Gmbh |
COMPOSITIONS AND METHODS THAT USE CDPK TYPE RNA INTERFERENCE FOR NEMATE CONTROL.
|
DE102007008596B4
(en)
|
2007-02-15 |
2010-09-02 |
Friedrich-Schiller-Universität Jena |
Biologically active molecules based on PNA and siRNA, methods for their cell-specific activation and application kit for administration
|
BRPI0808008B1
(en)
|
2007-02-16 |
2016-08-09 |
Basf Plant Science Gmbh |
isolated nucleic acid molecule, expression cassette, expression vector, methods for excising target sequences from a plant to produce a plant with increased yield, and / or increased stress tolerance, and / or increased nutritional quality, and / or increased or modified oil content of a seed or sprout for the plant, and use of the nucleic acid molecule
|
WO2008103378A2
(en)
|
2007-02-20 |
2008-08-28 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
WO2008103643A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Monsanto Technology, Llc |
Invertebrate micrornas
|
WO2008106102A2
(en)
*
|
2007-02-26 |
2008-09-04 |
Quark Pharmaceuticals, Inc. |
Inhibitors of rtp801 and their use in disease treatment
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
AU2008220438A1
(en)
*
|
2007-02-27 |
2008-09-04 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
WO2008104978A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
US9340601B2
(en)
*
|
2007-03-01 |
2016-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Splice variants of the EGF receptor
|
US8318921B2
(en)
*
|
2007-03-01 |
2012-11-27 |
California Institute Of Technology |
Triggered RNAi
|
WO2008109432A2
(en)
*
|
2007-03-02 |
2008-09-12 |
The Board Of Regents Of The University Of Texas System |
Therapeutic targeting of interleukins using sirna in neutral liposomes
|
EP2243834A1
(en)
|
2007-03-05 |
2010-10-27 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US8080648B1
(en)
|
2007-03-09 |
2011-12-20 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Pesticidal double stranded RNA composition and method of use thereof
|
JP2010521460A
(en)
*
|
2007-03-12 |
2010-06-24 |
アンティジェン・エクスプレス・インコーポレーテッド |
Ii-RNAi involvement Ii suppression in cancer immunotherapy
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
US7812002B2
(en)
*
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
ES2538217T3
(en)
|
2007-03-21 |
2015-06-18 |
Brookhaven Science Associates, Llc |
Combined fork antisense compositions and methods to modulate expression
|
CA2678901C
(en)
|
2007-03-26 |
2017-11-14 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods for modulating embryonic stem cell differentiation
|
PE20090064A1
(en)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
|
WO2012070037A2
(en)
|
2010-11-22 |
2012-05-31 |
Rosetta Genomics Ltd. |
Methods and materials for classification of tissue of origin of tumor samples
|
US20100273172A1
(en)
|
2007-03-27 |
2010-10-28 |
Rosetta Genomics Ltd. |
Micrornas expression signature for determination of tumors origin
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
EP2905336A1
(en)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of a gene from the ebola
|
WO2008124639A2
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Poly (amino acid) targeting moieties
|
EP1985295A1
(en)
*
|
2007-04-04 |
2008-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
WO2008130921A1
(en)
*
|
2007-04-16 |
2008-10-30 |
Modgene, Llc |
Methods and compositions for diagnosis and treatment of depression and anxiety
|
CA2584934A1
(en)
|
2007-04-17 |
2008-10-17 |
University Of Guelph |
Nitrogen-regulated sugar sensing gene and protein and modulation thereof
|
US8808747B2
(en)
*
|
2007-04-17 |
2014-08-19 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
US9556210B2
(en)
|
2007-04-23 |
2017-01-31 |
Sabag-Rfa Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
US9156865B2
(en)
|
2007-04-23 |
2015-10-13 |
Deliversir Ltd |
System for delivering therapeutic agents into living cells and cells nuclei
|
WO2008129548A2
(en)
|
2007-04-23 |
2008-10-30 |
Segev Laboratories Limited |
A system for delivering therapeutic agents into living cells and cells nuclei
|
WO2009014565A2
(en)
|
2007-04-26 |
2009-01-29 |
Ludwig Institute For Cancer Research, Ltd. |
Methods for diagnosing and treating astrocytomas
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
MX2009011523A
(en)
|
2007-04-27 |
2009-11-09 |
Dow Global Technologies Inc |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins.
|
EP3196310B1
(en)
|
2007-04-27 |
2020-07-08 |
The Regents of The University of California |
Plant co2 sensors, nucleic acids encoding them, and methods for making and using them
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
EP2152877A2
(en)
*
|
2007-05-02 |
2010-02-17 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2155860B1
(en)
|
2007-05-03 |
2014-08-27 |
The Brigham and Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
US20100115635A1
(en)
*
|
2007-05-04 |
2010-05-06 |
Abbott Laboratories |
Methods for Assessing the Delivery of Exogenous Agents
|
EP2152888A2
(en)
|
2007-05-04 |
2010-02-17 |
BASF Plant Science GmbH |
Enhancement of seed oil / amino acid content by combinations of pyruvate kinase subunits
|
US20100251392A1
(en)
*
|
2007-05-04 |
2010-09-30 |
Abbott Laboratories |
Methods for assessing the delivery of exogenous agents
|
EP3434259A1
(en)
|
2007-05-04 |
2019-01-30 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
EP2155910A4
(en)
*
|
2007-05-08 |
2010-06-02 |
Univ Duke |
Compositions and methods for characterizing and regulating olfactory sensation
|
KR101563753B1
(en)
|
2007-05-11 |
2015-10-27 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Methods of treatment of skin ulcers
|
MX2009012188A
(en)
|
2007-05-11 |
2010-02-24 |
Univ Jefferson |
Methods of treatment and prevention of neurodegenerative diseases and disorders.
|
WO2008143786A1
(en)
*
|
2007-05-14 |
2008-11-27 |
The Rockefeller University |
Production of artificial micrornas using synthetic microrna precursors
|
EP1992699A1
(en)
*
|
2007-05-15 |
2008-11-19 |
Genoplante-Valor |
Method for increasing the resistance of a plant to endoparasitic nematodes
|
US9217151B2
(en)
|
2007-05-16 |
2015-12-22 |
California Institute Of Technology |
Versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
|
US20090232893A1
(en)
*
|
2007-05-22 |
2009-09-17 |
Bader Andreas G |
miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
MX2009012568A
(en)
|
2007-05-22 |
2009-12-08 |
Mdrna Inc |
Hydroxymethyl substituted rna oligonucleotides and rna complexes.
|
CN101765660B
(en)
|
2007-05-22 |
2013-10-23 |
巴斯夫植物科学有限公司 |
Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
UA100855C2
(en)
|
2007-05-23 |
2013-02-11 |
Сингента Партисипейшнс Аг |
Polynucleotide markers
|
CA2688417C
(en)
|
2007-05-24 |
2017-04-25 |
Calcimedica, Inc. |
Calcium channel proteins and uses thereof
|
AU2008287542C1
(en)
|
2007-06-01 |
2015-01-22 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
CN101801419A
(en)
*
|
2007-06-08 |
2010-08-11 |
米尔纳疗法公司 |
Gene and path as the miR-34 regulation and control for the treatment of the target of intervening
|
US20100240597A1
(en)
|
2007-06-15 |
2010-09-23 |
Arkansas State University |
Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
|
US20100273854A1
(en)
*
|
2007-06-15 |
2010-10-28 |
Hagar Kalinski |
Compositions and methods for inhibiting nadph oxidase expression
|
WO2008157299A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
CA3065983C
(en)
|
2007-06-22 |
2022-07-26 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Inhibitors of ncca-atp channels for therapy
|
SI2170403T1
(en)
*
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US20110111496A1
(en)
*
|
2007-06-29 |
2011-05-12 |
Chiang Li |
BACTERIA-MEDIATED GENE MODULATION VIA microRNA MACHINERY
|
JP2010532360A
(en)
*
|
2007-07-02 |
2010-10-07 |
ワイス・エルエルシー |
Modulator of AXL for use in the treatment of bone disorders
|
AU2008272051A1
(en)
|
2007-07-03 |
2009-01-08 |
Cytopathfinder, Inc. |
Treatment of influenza
|
BRPI0814189A2
(en)
|
2007-07-05 |
2015-03-03 |
Novartis Ag |
DOUBLE FILM RIBONUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND ITS USES, METHOD FOR INHIBITING PHOSPHYDYLINOSITOL 4-KINASE EXPRESSION, VECTOR AND USE OF A COMPOUND THAT SELECTIVELY INHIBITS PHOSPHTIDYLINOSITOL-4 PHASE.
|
CA2692441C
(en)
|
2007-07-06 |
2020-01-21 |
The Regents Of The University Of Michigan |
Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
|
JP2010532662A
(en)
*
|
2007-07-06 |
2010-10-14 |
イントラダイム コーポレイション |
Methods and compositions for the treatment of cancer and other angiogenesis related diseases
|
CN101821407B
(en)
|
2007-07-10 |
2013-09-18 |
纽瑞姆制药(1991)有限公司 |
CD44 splice variants in neurodegenerative diseases
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
AU2008317495B2
(en)
|
2007-08-02 |
2013-08-01 |
Novimmune S.A. |
Anti-RANTES antibodies and methods of use thereof
|
US20090044296A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Cornell Research Foundation, Inc. |
Hrpn interactors and uses thereof
|
US8642846B2
(en)
|
2007-08-13 |
2014-02-04 |
Commonwealth Scientific And Industrial Research Organisation |
Barley with low levels of hordeins
|
CN101932708A
(en)
|
2007-08-14 |
2010-12-29 |
联邦科学工业研究组织 |
Improved gene silencing methods
|
EP2179292B1
(en)
|
2007-08-16 |
2012-11-28 |
The Regents of the University of Michigan |
Metabolomic profiling of prostate cancer
|
CN102316888A
(en)
|
2007-08-23 |
2012-01-11 |
利兰斯坦福青年大学托管委员会 |
Synaptogenic regulation and control
|
JP2010536388A
(en)
|
2007-08-30 |
2010-12-02 |
ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
Dendritic cell markers and uses thereof
|
WO2009033027A2
(en)
*
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009108217A2
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
US20100280097A1
(en)
*
|
2007-09-18 |
2010-11-04 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
EP2548962B1
(en)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof
|
CN101878307B
(en)
|
2007-09-27 |
2017-07-28 |
陶氏益农公司 |
Using sour 3 phosphate synthase genes of 5 enolpyrul-shikimates as the engineered zinc finger of target
|
AU2008307371B2
(en)
|
2007-10-03 |
2015-05-28 |
Bp Corporation North America Inc. |
Xylanases, nucleic acids encoding them and methods for making and using them
|
AU2008306455C1
(en)
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
JP2010539990A
(en)
*
|
2007-10-04 |
2010-12-24 |
ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム |
Method for regulating gene expression using agRNA and gapmer targeting antisense transcript
|
WO2009045536A2
(en)
*
|
2007-10-05 |
2009-04-09 |
The University Of North Carolina At Chapel Hill |
Receptor targeted oligonucleotides
|
US10736848B2
(en)
|
2007-10-12 |
2020-08-11 |
Massachusetts Institute Of Technology |
Vaccine nanotechnology
|
EP2200649A4
(en)
|
2007-10-19 |
2012-09-26 |
Univ California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
PE20091163A1
(en)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
ANTIBODIES FOR GDF8
|
EP2217706B1
(en)
*
|
2007-11-12 |
2015-05-27 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
|
JP5695422B2
(en)
|
2007-11-27 |
2015-04-08 |
コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション |
Modified starch metabolism plant
|
EP2065037A1
(en)
|
2007-11-27 |
2009-06-03 |
DKFZ Deutsches Krebsforschungszentrum |
Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)
|
WO2009070805A2
(en)
*
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
US7968525B1
(en)
|
2007-12-03 |
2011-06-28 |
University Of Florida Research Foundation, Inc. |
Use of RNA interference to validate new termiticide target sites and a method of termite control
|
EP2224822B1
(en)
|
2007-12-06 |
2014-05-21 |
Novozymes A/S |
Polypeptides having acetylxylan esterase activity and polynucleotides encoding same
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
NZ585784A
(en)
*
|
2007-12-13 |
2012-09-28 |
Alnylam Pharmaceuticals Inc |
siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
|
EP2225380A2
(en)
*
|
2007-12-17 |
2010-09-08 |
BASF Plant Science GmbH |
Lipid metabolism protein and uses thereof i (bzip transcription factor)
|
EP2072528A1
(en)
|
2007-12-19 |
2009-06-24 |
Labeit, Mr. Siegfried |
A host cell deficient for MuRF1 and MuRF2
|
BRPI0821230A2
(en)
|
2007-12-19 |
2019-09-24 |
Novozymes As |
"nucleic acid construct, recombinant host microbial banknote, methods for producing a polypeptide having cellulolytic enhancing activity, for producing a precursor banknote mutant, for inhibiting expression of a cellulolytic enhancing activity polypeptide in a cell, for producing a protein" , to degrade or convert a cellulosic material, and to ferment a cellulosic material "
|
WO2009085273A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
EP2237786A2
(en)
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of inhibitors of connexin43 for treatment of fibrotic conditions
|
US20090186358A1
(en)
*
|
2007-12-21 |
2009-07-23 |
Wyeth |
Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
|
US20110092449A1
(en)
*
|
2007-12-21 |
2011-04-21 |
Bradford James Duft |
Treatment of fibrotic conditions
|
WO2009082208A2
(en)
|
2007-12-21 |
2009-07-02 |
Keygene N.V. |
Trichome specific promoters
|
CN101952444A
(en)
|
2007-12-21 |
2011-01-19 |
巴斯夫植物科学有限公司 |
Plants with increased yield (KO NUE)
|
US20090192114A1
(en)
*
|
2007-12-21 |
2009-07-30 |
Dmitriy Ovcharenko |
miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
|
CA2710543A1
(en)
|
2007-12-28 |
2009-07-09 |
Swetree Technologies Ab |
Woody plants having improved growth charateristics and method for making the same using transcription factors
|
US20090226914A1
(en)
*
|
2007-12-31 |
2009-09-10 |
Bates Paula J |
Methods and products to target, capture and characterize stem cells
|
DK2238261T3
(en)
|
2008-01-03 |
2014-02-10 |
Verenium Corp |
Isomerases, nucleic acids encoding them and processes for their preparation and use
|
PL2238242T3
(en)
|
2008-01-03 |
2015-06-30 |
Basf Enzymes Llc |
Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
|
WO2009097077A2
(en)
*
|
2008-01-07 |
2009-08-06 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
TW200930398A
(en)
*
|
2008-01-11 |
2009-07-16 |
Univ Chang Gung |
RNAi sequence, inhibitor, and inhibition method that specifically inhibits expression of 78-kDA glucose-regulated protein
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
WO2009094647A2
(en)
|
2008-01-25 |
2009-07-30 |
Introgen Therapeutics, Inc. |
P53 biomarkers
|
EP2234483A4
(en)
|
2008-01-27 |
2011-04-27 |
Rosetta Genomics Ltd |
Methods and compositions for diagnosing complications of pregnancy
|
US20090205078A1
(en)
|
2008-02-05 |
2009-08-13 |
Pioneer Hi-Bred International, Inc. |
Maize Leaf- and Stalk-Preferred Promoter
|
EP2260110B1
(en)
*
|
2008-02-08 |
2014-11-12 |
Asuragen, INC. |
miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
|
US10131904B2
(en)
*
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
DE102009043743B4
(en)
|
2009-03-13 |
2016-10-13 |
Friedrich-Schiller-Universität Jena |
Cell-specific molecules based on siRNA as well as application kits for their production and use
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
KR101397407B1
(en)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2009111643A2
(en)
*
|
2008-03-06 |
2009-09-11 |
Asuragen, Inc. |
Microrna markers for recurrence of colorectal cancer
|
EP2250265A1
(en)
*
|
2008-03-12 |
2010-11-17 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
EP2268316A4
(en)
*
|
2008-03-20 |
2011-05-25 |
Quark Pharmaceuticals Inc |
NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
|
US20090253780A1
(en)
*
|
2008-03-26 |
2009-10-08 |
Fumitaka Takeshita |
COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
|
BRPI0911332A2
(en)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
compositions and use of epas1 inhibitors
|
WO2009126726A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
CN102027121B
(en)
|
2008-04-10 |
2017-08-08 |
孟山都技术公司 |
Method and composition for root knot nematode control
|
WO2009125401A2
(en)
|
2008-04-10 |
2009-10-15 |
Rosetta Genomics Ltd. |
Compositions and methods for enhancing oil content in plants
|
AU2009238629C1
(en)
|
2008-04-14 |
2015-04-30 |
Sangamo Therapeutics, Inc. |
Linear donor constructs for targeted integration
|
WO2009144704A2
(en)
*
|
2008-04-15 |
2009-12-03 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS FOR INHIBITING NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
WO2009137807A2
(en)
*
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
WO2009143391A2
(en)
*
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
EP2293800B1
(en)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
WO2010005527A1
(en)
|
2008-06-30 |
2010-01-14 |
Angioblast Systems, Inc. |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP2690175B1
(en)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
|
AU2009290625B2
(en)
|
2008-09-10 |
2014-12-11 |
University Of Bradford |
Compositions and methods for modulating skin pigmentation
|
CA2734922C
(en)
|
2008-09-15 |
2020-01-14 |
Laetitia Malphettes |
Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
|
WO2010033560A2
(en)
|
2008-09-16 |
2010-03-25 |
University Of Maryland, Baltimore |
Sur1 inhibitors for therapy
|
EP2165710A1
(en)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
BRPI0919473A2
(en)
|
2008-09-26 |
2017-08-29 |
Oncomed Pharm Inc |
FRIZZLED BINDING AGENTS AND THEIR USES
|
KR101647522B1
(en)
|
2008-09-29 |
2016-08-10 |
몬산토 테크놀로지 엘엘씨 |
Soybean transgenic event mon87705 and methods for detection thereof
|
US8298794B2
(en)
|
2008-10-09 |
2012-10-30 |
Ceres, Inc. |
Cinnamyl-alcohol dehydrogenases
|
WO2010042933A2
(en)
|
2008-10-10 |
2010-04-15 |
Northwestern University |
Inhibition and treatment of prostate cancer metastasis
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8591905B2
(en)
*
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343498B2
(en)
*
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
KR20110071017A
(en)
|
2008-10-16 |
2011-06-27 |
마리나 바이오테크, 인크. |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
BRPI0920582A2
(en)
*
|
2008-10-16 |
2019-08-27 |
Cytonics Corp |
biomarkers and methods for detecting and treating spinal and joint pain
|
LT2937418T
(en)
|
2008-10-20 |
2018-02-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
US20100168205A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Alnylam Pharmaceuticals, Inc. |
Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
|
CA2741664C
(en)
|
2008-10-31 |
2014-12-23 |
Japan Science And Technology Agency |
Method for selective control of helper t cell function
|
EP2350291A4
(en)
|
2008-11-03 |
2012-02-22 |
Swetree Technologies Ab |
Vegetabile material, plants and a method of producing a plant having altered lignin properties
|
US9289475B2
(en)
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
US8710104B2
(en)
*
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
CA2743057C
(en)
|
2008-11-07 |
2019-11-26 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
|
WO2010054379A2
(en)
|
2008-11-10 |
2010-05-14 |
The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services |
Gene signature for predicting prognosis of patients with solid tumors
|
EP2364323A2
(en)
*
|
2008-11-10 |
2011-09-14 |
Wyeth LLC |
Temperature-induced polynucleotides and uses therefor
|
US20100179213A1
(en)
*
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
US8734853B2
(en)
|
2008-11-17 |
2014-05-27 |
University Of North Texas Health Science Center At Fort Worth |
HDL particles for delivery of nucleic acids
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
EP2857515B1
(en)
|
2008-11-20 |
2018-02-21 |
Novozymes Inc. |
Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
|
SG171879A1
(en)
|
2008-12-03 |
2011-07-28 |
Marina Biotech Inc |
Usirna complexes
|
EP2370092A1
(en)
|
2008-12-03 |
2011-10-05 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
WO2010065830A1
(en)
|
2008-12-04 |
2010-06-10 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
SG171952A1
(en)
|
2008-12-04 |
2011-07-28 |
Opko Ophthalmics Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
US8497075B2
(en)
|
2008-12-09 |
2013-07-30 |
Novartis Ag |
Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
|
US8324368B2
(en)
|
2008-12-10 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
EP2198879A1
(en)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
WO2010068800A1
(en)
|
2008-12-12 |
2010-06-17 |
Novozymes, Inc. |
Polypeptides having aspartic endopeptidase activity and polynucleotides encoding same
|
EP2376527A1
(en)
|
2008-12-12 |
2011-10-19 |
Novozymes Inc. |
Polypeptides having lipase activity and polynucleotides encoding same
|
PL2376638T3
(en)
|
2008-12-12 |
2014-01-31 |
Basf Plant Science Gmbh |
Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
|
WO2010074972A1
(en)
|
2008-12-15 |
2010-07-01 |
Novozymes, Inc. |
Polypeptides having catalase activity and polynucleotides encoding same
|
WO2010074955A1
(en)
|
2008-12-16 |
2010-07-01 |
Novozymes, Inc. |
Polypeptides having carboxypeptidase activity and polynucleotides encoding same
|
US20110271407A1
(en)
|
2008-12-16 |
2011-11-03 |
Novozymes, Inc. |
Polypeptides Having Alpha-Mannosidase Activity And Polynucleotides Encoding Same
|
US8329986B2
(en)
|
2008-12-17 |
2012-12-11 |
Dow Agrosciences, Llc |
Targeted integration into the Zp15 locus
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
CN102325534B
(en)
|
2008-12-18 |
2016-02-17 |
戴瑟纳制药公司 |
The DICER enzyme substrates extended and the method for specific inhibition of gene expression
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
JP2012513464A
(en)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
Phosphodiesterase inhibitors and uses thereof
|
EP2201982A1
(en)
|
2008-12-24 |
2010-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Histamine H4 receptor antagonists for the treatment of vestibular disorders
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
MX2011007350A
(en)
*
|
2009-01-08 |
2011-09-06 |
Univ Northwestern |
Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates.
|
BRPI1004572A2
(en)
|
2009-01-09 |
2016-04-05 |
Univ Michigan |
"Recurrent genetic fusions in cancer
|
WO2010088387A1
(en)
|
2009-01-28 |
2010-08-05 |
Novozymes, Inc. |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
US8629324B2
(en)
|
2009-01-30 |
2014-01-14 |
Novozymes, Inc. |
Polypeptides having expansin activity and polynucleotides encoding same
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US8309530B2
(en)
*
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
EP2395996A1
(en)
|
2009-02-13 |
2011-12-21 |
Indiana University Research and Technology Corporation |
Compounds and methods for inhibiting mmp2 and mmp9
|
BRPI1008606A2
(en)
|
2009-02-13 |
2017-05-30 |
Univ California |
plant, plant cell, seed, flower, leaf or fruit, method for increasing stress tolerance in a plant, cassette and expression vector, method for preparing a plant, agricultural chemical formulation, and methods for increasing stress tolerance in a plant and to identify an agent that agonizes a pyr / pyl polypeptide.
|
JP2012518657A
(en)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Combined anticancer treatment
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
JP2012520685A
(en)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107955A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
US8748493B2
(en)
|
2009-03-20 |
2014-06-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
|
EP3293257B1
(en)
|
2009-03-20 |
2021-08-11 |
Mesoblast, Inc. |
Production of reprogrammed pluripotent cells
|
EP2408923A1
(en)
|
2009-03-20 |
2012-01-25 |
BASF Plant Science Company GmbH |
Nematode-resistant transgenic plants
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
JP2012521765A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of intracellular adhesion molecule 1 (ICAM-1) gene expression using small interfering nucleic acids (siNA)
|
EP2411018A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
EP2411019A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521760A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
US20100257634A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Venganza Inc. |
Bioassay for gene silencing constructs
|
AU2010232410B2
(en)
|
2009-04-03 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
WO2010115874A1
(en)
|
2009-04-07 |
2010-10-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
MX2011011134A
(en)
*
|
2009-04-21 |
2012-01-31 |
Selecta Biosciences Inc |
Immunonanotherapeutics providing a th1-biased response.
|
RU2561463C2
(en)
|
2009-04-22 |
2015-08-27 |
Басф Плант Сайенс Компани Гмбх |
Whole seed specific promoter
|
EP2243828A1
(en)
|
2009-04-24 |
2010-10-27 |
DKFZ Deutsches Krebsforschungszentrum |
Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
|
WO2010124231A2
(en)
*
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
EP2427180B1
(en)
|
2009-05-05 |
2016-04-13 |
Beeologics Inc. |
Prevention and treatment of nosema disease in bees
|
MY186558A
(en)
*
|
2009-05-13 |
2021-07-27 |
Malaysian Palm Oil Board |
A constitutive promoter from oil palm type 2
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
JP5955767B2
(en)
|
2009-05-20 |
2016-07-20 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
Serotonin 5-HT3 receptor antagonist for use in the treatment of injured vestibular disorders
|
EP2432499A2
(en)
|
2009-05-20 |
2012-03-28 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2253316B1
(en)
|
2009-05-20 |
2013-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
|
DK2432797T3
(en)
|
2009-05-21 |
2017-01-16 |
Basf Enzymes Llc |
PHYTASES, NUCLEIC ACIDS, CODING THESE, AND METHODS OF PRODUCING AND USING THEREOF
|
JP5875976B2
(en)
|
2009-06-01 |
2016-03-02 |
ヘイロー−バイオ アールエヌエーアイ セラピューティクス, インコーポレイテッド |
Polynucleotides, compositions and methods for their use for multivalent RNA interference
|
DK2438163T3
(en)
|
2009-06-02 |
2015-04-20 |
Novozymes Inc |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding them
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
AU2010256356B2
(en)
|
2009-06-05 |
2015-07-16 |
University Of Florida Research Foundation, Inc. |
Isolation and targeted suppression of lignin biosynthetic genes from sugarcane
|
EP2440664B1
(en)
|
2009-06-08 |
2021-04-21 |
Nunhems B.V. |
Drought tolerant plants
|
WO2010147825A1
(en)
|
2009-06-09 |
2010-12-23 |
Pioneer Hi-Bred International, Inc. |
Early endosperm promoter and methods of use
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
CN104651408A
(en)
|
2009-06-15 |
2015-05-27 |
阿尔尼拉姆医药品有限公司 |
Lipid formulated siRNA targeted to PCSK9 gene
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
US20100324124A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Compositions and methods relating to DNA-based particles
|
US20100323018A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
US20120142609A1
(en)
|
2009-06-26 |
2012-06-07 |
Abdoulaye Sene |
Non human animal models for increased retinal vascular permeability
|
AU2010273756A1
(en)
|
2009-06-30 |
2011-11-24 |
E. I. Du Pont De Nemours And Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase
|
BR112012000260B1
(en)
|
2009-07-07 |
2020-11-17 |
Novozymes A/S |
transgenic microbial host cell, methods to produce a polypeptide, to produce a mutant of a precursor cell, to inhibit expression of a polypeptide, to produce a protein, to degrade or convert a cellulosic material, to produce a fermentation product, to ferment a cellulosic material, nucleic acid constructs, expression vector, isolated polypeptide having cellulolytic intensification activity, and isolated polynucleotide that encodes the same
|
CN102481256B
(en)
|
2009-07-09 |
2015-02-25 |
玛瑞纳生物技术有限公司 |
Amphoteric liposomes comprising imino lipids
|
US8921657B2
(en)
|
2009-07-10 |
2014-12-30 |
Basf Plant Science Company Gmbh |
Expression cassettes for endosperm-specific expression in plants
|
BR112012000908A2
(en)
|
2009-07-14 |
2019-09-24 |
Mayo Found Medical Education & Res |
release of active agents via peptide-mediated blood-brain barrier in non-covalent association
|
CN102573451A
(en)
|
2009-07-20 |
2012-07-11 |
希尔雷斯股份有限公司 |
Transgenic plants having increased biomass
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
IN2012DN00303A
(en)
|
2009-07-24 |
2015-05-08 |
Univ California |
|
WO2011014458A1
(en)
|
2009-07-28 |
2011-02-03 |
Novozymes, Inc. |
Polypeptides having phytase activity and polynucleotides encoding same
|
CA2806295A1
(en)
*
|
2009-08-03 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating insects
|
WO2011017315A2
(en)
*
|
2009-08-03 |
2011-02-10 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
US8822144B2
(en)
|
2009-08-19 |
2014-09-02 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
US20120258093A1
(en)
|
2009-08-20 |
2012-10-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
AU2010286111A1
(en)
|
2009-08-21 |
2012-02-16 |
Beeologics Inc. |
Preventing and curing beneficial insect diseases via plant transcribed molecules
|
US8039613B2
(en)
|
2009-08-28 |
2011-10-18 |
Promega Corporation |
Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
|
US8222397B2
(en)
*
|
2009-08-28 |
2012-07-17 |
Promega Corporation |
Methods of optimal purification of nucleic acids and kit for use in performing such methods
|
US8741649B2
(en)
|
2009-09-04 |
2014-06-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for enhancing genome stability and telomere elongation in embryonic stem cells
|
ES2655079T3
(en)
|
2009-09-10 |
2018-02-16 |
Merck Sharp & Dohme Corp. |
Use of IL-33 antagonists to treat fibrotic diseases
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
CA2774326C
(en)
|
2009-09-14 |
2023-11-07 |
Donald Bellgrau |
Modulation of yeast-based immunotherapy products and responses
|
DK3269804T3
(en)
|
2009-09-17 |
2020-11-23 |
Novozymes Inc |
POLYPEPTIDES WITH CELLULOLYSIS IMPROVING ACTIVITY AND POLYNUCLEOTIDES ENCODING THEM
|
CN102712916B
(en)
|
2009-09-18 |
2015-11-25 |
诺维信股份有限公司 |
There are the polypeptide of beta-glucosidase activity and the polynucleotide of this polypeptide of coding
|
WO2011036118A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
CN102695719B
(en)
|
2009-09-29 |
2016-03-09 |
诺维信股份有限公司 |
There are the polypeptide of cellulolytic enhancing activity and the polynucleotide of this polypeptide of coding
|
DK2483403T3
(en)
|
2009-09-29 |
2018-02-12 |
Novozymes Inc |
POLYPEPTIDES WITH XYLANASE ACTIVITY AND POLYNUCLEOTIDES CODING THEM
|
CN108165542A
(en)
|
2009-09-30 |
2018-06-15 |
诺维信股份有限公司 |
Polypeptide with cellulolytic enhancing activity and the polynucleotides for encoding the polypeptide
|
CA2775244A1
(en)
|
2009-09-30 |
2011-04-07 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
UA109884C2
(en)
|
2009-10-16 |
2015-10-26 |
|
A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
|
UA111708C2
(en)
|
2009-10-16 |
2016-06-10 |
Бандж Ойлз, Інк. |
METHOD OF OIL REFINING
|
EP2490696A1
(en)
|
2009-10-20 |
2012-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
BR112012009044A2
(en)
|
2009-10-26 |
2015-09-01 |
Pioneer Hi Bred Int |
Isolated nucleic acid molecule, expression cassette, vector, plant cell, plant, transgenic seed, method for expressing a polynucleotide in a plant or plant cell and method for expressing a polynucleotide, preferably in somatic egg tissues of a plant
|
BR112012006847A2
(en)
|
2009-10-29 |
2015-09-08 |
Novozymes As |
polynucleotide polypeptide, recombinant host cell, methods for producing the polypeptide for producing a parent cell mutant, for inhibiting expression of a polypeptide, for producing a protein, for degrading or converting a cellulosic material, for producing a fermentation product, for produce a fermentation product and to ferment a cellulosic material, transgenic plant, part of the plant or plant cell, double stranded inhibitory RNA molecule, and, composition.
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
US9534211B2
(en)
|
2009-11-06 |
2017-01-03 |
Novozymes A/S |
Polypeptides having xylanase activity and polynucleotides encoding same
|
WO2011054916A1
(en)
|
2009-11-06 |
2011-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of atherosclerosis
|
WO2011057086A1
(en)
|
2009-11-06 |
2011-05-12 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US8901097B2
(en)
|
2009-11-08 |
2014-12-02 |
Quark Pharmaceuticals, Inc. |
Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
|
EP2322927A1
(en)
|
2009-11-16 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
|
EP2322619A1
(en)
|
2009-11-17 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Inhibitors of centrosomal clustering
|
EP2501414B1
(en)
|
2009-11-17 |
2018-01-10 |
The Trustees Of The University Of Pennsylvania |
Smndelta7 degron: novel compositions and methods of use
|
EP3037435B1
(en)
|
2009-11-17 |
2019-08-07 |
MUSC Foundation for Research Development |
Human monoclonal antibodies to human nucleolin
|
JP2013511990A
(en)
|
2009-11-26 |
2013-04-11 |
クォーク ファーマシューティカルズ インコーポレーティッド |
SiRNA compounds containing terminal substitutions
|
JP5077901B2
(en)
|
2009-11-27 |
2012-11-21 |
独立行政法人科学技術振興機構 |
Screening method for antihyperlipidemic agent
|
BR112012013156A2
(en)
|
2009-12-03 |
2017-06-13 |
Basf Plant Science Co Gmbh |
expression cassette, vector, host cell, transgenic plant tissue and method for producing a transgenic plant tissue
|
WO2011071916A2
(en)
|
2009-12-07 |
2011-06-16 |
The Johns Hopkins University |
Sr-bi as a predictor of human female infertility and responsiveness to treatment
|
CA2782545A1
(en)
|
2009-12-09 |
2011-06-16 |
Basf Plant Science Company Gmbh |
Methods for increasing the resistance of plants to fungi by silencing the fungal smt1-gene
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
US20120283190A1
(en)
|
2009-12-09 |
2012-11-08 |
Institut National de la Santé et de la Recherche Medicale (INSERM) |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
EP3012324A3
(en)
|
2009-12-09 |
2016-07-06 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
WO2011072243A1
(en)
|
2009-12-10 |
2011-06-16 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
EP2513308B1
(en)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation of pilr to treat immune disorders
|
KR101605932B1
(en)
*
|
2009-12-18 |
2016-03-24 |
노파르티스 아게 |
Organic compositions to treat hsf1-related diseases
|
WO2011079077A1
(en)
|
2009-12-23 |
2011-06-30 |
Gradalis, Inc. |
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
EA026374B1
(en)
|
2009-12-23 |
2017-04-28 |
Новартис Аг |
Lipids, lipid compositions, and methods of using them
|
WO2011079070A1
(en)
|
2009-12-23 |
2011-06-30 |
Gradalis, Inc. |
Furin-knockdown bi-functional rna
|
WO2011080261A1
(en)
|
2009-12-28 |
2011-07-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for improved cardiomyogenic differentiation of pluripotent cells
|
DK2493491T3
(en)
|
2009-12-29 |
2014-06-30 |
Hills Pet Nutrition Inc |
COMPOSITIONS, INCLUDING GIFTING FOR THE PURPOSE OR PREVENTION OF INFLAMMATORY CONDITIONS OF CATS AND DOGS
|
EP2521782B1
(en)
|
2010-01-05 |
2019-04-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
TWI535445B
(en)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt antagonists and methods of treatment and screening
|
DE102010004957A1
(en)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologically active molecules for influencing virus, bacterial, parasite-infected cells and / or tumor cells and methods for their use
|
SI2523661T1
(en)
|
2010-01-15 |
2017-09-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nkcc inhibitors for the treatment of autism
|
CA2787994C
(en)
|
2010-01-26 |
2021-01-12 |
National Jewish Health |
Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
JP2013519869A
(en)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
Methods and compounds for muscle growth
|
WO2011104153A1
(en)
|
2010-02-23 |
2011-09-01 |
Basf Plant Science Company Gmbh |
Nematode-resistant transgenic plants
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109618A2
(en)
|
2010-03-03 |
2011-09-09 |
E. I. Du Pont De Nemours And Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides
|
WO2011116209A2
(en)
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
CN105131067B
(en)
|
2010-03-24 |
2019-02-19 |
雷克西制药公司 |
RNA in skin and fibrotic conditions is interfered
|
CN106074591B
(en)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
RNA interference in ocular symptoms
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
US8945927B2
(en)
|
2010-03-29 |
2015-02-03 |
Universite De Strasbourg |
Polymers for delivering molecules of interest
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
NZ602700A
(en)
|
2010-04-01 |
2014-10-31 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
US8507663B2
(en)
|
2010-04-06 |
2013-08-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US20130190383A1
(en)
|
2010-04-26 |
2013-07-25 |
Marina Biotech, Inc. |
Nucleic acid compounds with conformationally restricted monomers and uses thereof
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
AU2011248184B2
(en)
|
2010-05-04 |
2015-12-17 |
Board Of Regents, The University Of Texas System |
Detection and treatment of fibrosis
|
WO2011140329A1
(en)
|
2010-05-06 |
2011-11-10 |
Ceres, Inc. |
Transgenic plants having increased biomass
|
ES2641144T3
(en)
|
2010-05-10 |
2017-11-07 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and compositions for the treatment of fluid accumulation in and / or under the retina
|
AU2011250904A1
(en)
|
2010-05-11 |
2012-11-08 |
Dow Agrosciences Llc |
spnK strains
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
KR101223660B1
(en)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient
|
EP2571987B1
(en)
|
2010-05-21 |
2017-03-01 |
Peptimed, Inc. |
Reagents for treating cancer
|
MX2012013713A
(en)
|
2010-05-26 |
2013-01-28 |
Selecta Biosciences Inc |
Nanocarrier compositions with uncoupled adjuvant.
|
CN107974457A
(en)
|
2010-05-28 |
2018-05-01 |
纽海姆有限公司 |
The plant of fruit size increase
|
US20130149320A1
(en)
|
2010-05-31 |
2013-06-13 |
Centre National De La Recherche Scientifique |
Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
|
EP2576579B1
(en)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
DE102010022937A1
(en)
|
2010-06-04 |
2011-12-08 |
Universitätsklinikum Jena |
Cell-specific activatable biologically active molecules based on siRNA, methods for their activation and application kit for administration
|
GB201009601D0
(en)
|
2010-06-08 |
2010-07-21 |
Devgen Private Ltd |
Method for down-grading gene expression in fungi
|
US9241944B2
(en)
|
2010-06-16 |
2016-01-26 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods and compositions for stimulating reepithelialisation during wound healing
|
EP2769985B1
(en)
|
2010-06-21 |
2017-12-06 |
Novozymes, Inc. |
Aspergillus aculeatus derived polypeptides having C4-dicarboxylic acid transporter activity and polynucleotides encoding same
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
WO2012000904A1
(en)
|
2010-06-28 |
2012-01-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of glaucoma
|
EP2588604B1
(en)
|
2010-06-30 |
2016-06-29 |
Novozymes, Inc. |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
CA2803609A1
(en)
|
2010-07-01 |
2012-01-05 |
E. I. Du Pont De Nemours And Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides
|
WO2012007945A2
(en)
|
2010-07-12 |
2012-01-19 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center |
Isolated polynucleotides and methods and plants using same for regulating plant acidity
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012019991A1
(en)
|
2010-08-09 |
2012-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of hiv-1 infections
|
BR112013003224A2
(en)
|
2010-08-13 |
2016-06-07 |
Pioneer Hi Bred Int |
"chimeric promoter construct, expression cassette, expression vector, method of obtaining a plant, method for regulating expression of a polynucleotide of interest, polynucleotide, method for expressing a polynucleotide of interest"
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP3636778B1
(en)
|
2010-08-18 |
2022-01-12 |
Fred Hutchinson Cancer Research Center |
Agents for use in treating facioscapulohumeral dystrophy (fshd)
|
CN103140582A
(en)
|
2010-08-24 |
2013-06-05 |
默沙东公司 |
Single-stranded rnai agents containing an internal, non-nucleic acid spacer
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20130212746A1
(en)
|
2010-08-30 |
2013-08-15 |
Novoyzmes A/S |
Polypeptides Having Hemicellulolytic Activity And Polynucleotides Encoding Same
|
WO2012030844A1
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US8624082B2
(en)
|
2010-08-30 |
2014-01-07 |
Novozymes A/S |
Polypeptides having xylanase activity and polynucleotides encoding same
|
DK2735611T3
(en)
|
2010-08-30 |
2019-01-28 |
Novozymes As |
POLYPEPTIDES WITH CELLULOLYSE INCREASING ACTIVITY AND POLYNUCLEOTIDES CODING THEM
|
EP2611901B1
(en)
|
2010-08-30 |
2016-05-11 |
Novozymes A/S |
Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
|
US9187742B2
(en)
|
2010-08-30 |
2015-11-17 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US20130224192A1
(en)
|
2010-09-02 |
2013-08-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for the prognosis of the progression of cancer
|
WO2012042289A1
(en)
|
2010-09-28 |
2012-04-05 |
Inserm ( Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bone density related diseases
|
ES2606140T3
(en)
|
2010-10-01 |
2017-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to predict progression and treat chronic kidney disease in a patient
|
US9234216B2
(en)
|
2010-10-06 |
2016-01-12 |
Bp Corporation North America Inc. |
Variant CBH I polypeptides
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
EP2627349B1
(en)
|
2010-10-15 |
2016-02-03 |
The Trustees of Columbia University in the City of New York |
Obesity-related genes and their proteins and uses thereof
|
US10004797B2
(en)
|
2010-10-27 |
2018-06-26 |
Harrisvaccines, Inc. |
Method of rapidly producing improved vaccines for animals
|
WO2012058223A1
(en)
|
2010-10-27 |
2012-05-03 |
Ceres, Inc. |
Transgenic plants having altered biomass composition
|
US8822427B2
(en)
|
2010-10-27 |
2014-09-02 |
Harrisvaccines |
Methods and compositions to protect aquatic invertebrates from disease
|
US10738326B2
(en)
|
2010-10-27 |
2020-08-11 |
Jichi Medical University |
Adeno-associated virus vector for gene transfer to nervous system cells
|
WO2012058073A2
(en)
|
2010-10-27 |
2012-05-03 |
Harrisvaccines, Inc. |
Methods and compositions to protect aquatic invertebrates from disease
|
ES2663009T3
(en)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
|
US8728804B2
(en)
|
2010-10-29 |
2014-05-20 |
Novozymes A/S |
Polypeptides having succinyl-CoA: acetoacetate transferase activity and polynucleotides encoding same
|
EP2635308A2
(en)
|
2010-11-01 |
2013-09-11 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
KR102027394B1
(en)
|
2010-11-02 |
2019-10-01 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
Methods for treating hair loss disorders
|
EP2635594B1
(en)
|
2010-11-04 |
2017-01-11 |
Novozymes Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
BR112013011025B1
(en)
|
2010-11-04 |
2021-03-02 |
Arista Cereal Technologies Pty Ltd |
method for producing wheat flour, wheat flour, food ingredient, food product, food production method and starch production method
|
AU2011325871B2
(en)
|
2010-11-05 |
2016-02-04 |
Medvet Science Pty Ltd |
Markers of endothelial progenitor cells and uses thereof
|
CN110123830A
(en)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
|
WO2012062220A1
(en)
|
2010-11-12 |
2012-05-18 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
EP2455456A1
(en)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Use of kinesin inhibitors in HIV infection treatment and a method for screening them
|
WO2012072681A1
(en)
|
2010-12-01 |
2012-06-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Diagnostic and treatment of chronic heart failure
|
WO2012074868A2
(en)
|
2010-12-03 |
2012-06-07 |
Ms Technologies, Llc |
Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
|
US9533041B2
(en)
|
2010-12-03 |
2017-01-03 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of heart failure
|
CA2818024C
(en)
|
2010-12-06 |
2019-09-24 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising positional modifications
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
US8575328B2
(en)
|
2010-12-14 |
2013-11-05 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Formicidae (ant) control using double-stranded RNA constructs
|
EP2655635A1
(en)
|
2010-12-22 |
2013-10-30 |
Pioneer Hi-Bred International, Inc. |
Viral promoter, truncations thereof, and methods of use
|
MX2013007087A
(en)
|
2010-12-22 |
2013-07-29 |
Du Pont |
Viral promoter, truncations thereof, and methods of use.
|
CA2822621C
(en)
|
2010-12-22 |
2020-12-15 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase modulators and uses thereof
|
US8883757B2
(en)
|
2011-01-03 |
2014-11-11 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
US8911729B2
(en)
|
2011-01-10 |
2014-12-16 |
The Regents Of The University Of Michigan |
Stem cell factor inhibitor
|
US9506048B2
(en)
|
2011-01-26 |
2016-11-29 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
MX2013007720A
(en)
|
2011-01-26 |
2013-08-09 |
Novozymes As |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same.
|
EP2487242A1
(en)
|
2011-02-09 |
2012-08-15 |
Ruprecht-Karls-Universität Heidelberg |
B-type plexin antagonists and uses thereof
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
CN104774871A
(en)
|
2011-02-14 |
2015-07-15 |
雷维维科公司 |
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
|
WO2012112411A1
(en)
|
2011-02-15 |
2012-08-23 |
Pioneer Hi-Bred International, Inc. |
Root-preferred promoter and methods of use
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
CA2828544A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
WO2012118910A2
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
US9409958B2
(en)
|
2011-03-10 |
2016-08-09 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
CN103562408A
(en)
|
2011-03-15 |
2014-02-05 |
犹他大学研究基金会 |
Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
US8648230B2
(en)
|
2011-03-18 |
2014-02-11 |
Ms Technologies, Llc |
Regulatory regions preferentially expressing in non-pollen plant tissue
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US8658783B2
(en)
|
2011-04-13 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
JP2014512008A
(en)
|
2011-04-13 |
2014-05-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel disease
|
KR101291668B1
(en)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
Shuttle Vectors for Mycobacteria-Escherichia coli and Uses Thereof
|
JP2014519813A
(en)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
|
US20140050710A1
(en)
|
2011-04-28 |
2014-02-20 |
Universite Montpellier I |
Methods for preparing accessory cells and uses thereof for preparing activated nk cells
|
MX2013012325A
(en)
|
2011-04-28 |
2013-11-01 |
Novozymes Inc |
Polypeptides having endoglucanase activity and polynucleotides encoding same.
|
BR112013027860A2
(en)
*
|
2011-04-29 |
2016-11-29 |
Pioneer Hi Bred Int |
isolated nucleic acid, plant or plant cell, method for increasing drain capacity, accelerating remobilization and / or grain senescence and drying in a plant, method for increasing drought tolerance in the absence of a productivity penalty under conditions without drought, expression cassette and method for reducing zmme293 expression or zmme293 activity in a plant
|
ES2553079T3
(en)
|
2011-05-03 |
2015-12-04 |
Dow Agrosciences Llc |
Improved production of spinosyns with proteins that bind to oxygen
|
WO2012151517A1
(en)
|
2011-05-05 |
2012-11-08 |
Coordinated Program Development, Llc |
Cochleate compositions and methods of making and using same
|
EP2527432A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Bi-directional cytosine deaminase-encoding selection marker
|
EP2527448A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi
|
ES2703133T3
(en)
|
2011-05-24 |
2019-03-07 |
Rosetta Genomics Ltd |
Methods and compositions for determining heart failure or a risk of heart failure
|
CA2836364C
(en)
|
2011-05-25 |
2021-01-26 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
WO2012170304A2
(en)
|
2011-06-02 |
2012-12-13 |
The Regents Of The University Of California |
Plants with elevated levels of glucan
|
WO2012167173A1
(en)
|
2011-06-02 |
2012-12-06 |
The University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(en)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Retinoid-liposomes for enhancing modulation of hsp47 expression
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
DK2718442T3
(en)
|
2011-06-10 |
2017-08-14 |
Temasek Life Sciences Laboratory Ltd |
GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR SUBPHYLA OF PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
US9228188B2
(en)
|
2011-06-21 |
2016-01-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
|
EP2723756B1
(en)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2012175711A1
(en)
|
2011-06-24 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
RS55088B1
(en)
|
2011-07-06 |
2016-12-30 |
Sykehuset Sorlandet Hf |
Egfr targeted therapy
|
US9441255B2
(en)
|
2011-07-21 |
2016-09-13 |
The Regents Of The University Of California |
Transcription factors for cellulosic enzyme production
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
CN103717735A
(en)
|
2011-07-22 |
2014-04-09 |
公立大学法人横滨市立大学 |
Technique for cleaving out part of poly(a) chain and/or 3'-terminal sequence of mRNA to inhibit translation reaction
|
EP2737083A1
(en)
|
2011-07-27 |
2014-06-04 |
INSERM (Institut National de la Santé et de la Recherche Scientifique) |
Methods for diagnosing and treating myhre syndrome
|
WO2013021062A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021065A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021059A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021064A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
CN103732740B
(en)
|
2011-08-10 |
2018-07-31 |
诺维信公司 |
Polypeptide with peroxidase activity and the polynucleotides for encoding the polypeptide
|
WO2013021060A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
CN103827297B
(en)
|
2011-08-10 |
2018-06-22 |
诺维信公司 |
Polypeptide with peroxidase activity and the polynucleotides for encoding the polypeptide
|
MX2014001689A
(en)
*
|
2011-08-12 |
2014-05-27 |
Bayer Cropscience Nv |
Guard cell-specific expression of transgenes in cotton.
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
BR112014004186B1
(en)
|
2011-08-24 |
2020-12-15 |
Novozymes, Inc. |
ENZYMATIC COMPOSITION, RECOMBINANT FILAMENT FUNGUS HOSTING CELL, METHOD TO PRODUCE AN ENZYMATIC COMPOSITION, PROCESSES TO DEGRAD A CELLULOSIC MATERIAL, TO SYNTHESIZE A FERMENTATION PRODUCT, AND, TO FERMENT A CLEAN MATERIAL
|
CA2846391A1
(en)
|
2011-08-24 |
2013-02-28 |
Novozymes, Inc. |
Aspergillus fumigatus cellulolytic enzyme compositions and uses thereof
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
EP2750767A4
(en)
|
2011-09-02 |
2015-10-14 |
Univ Columbia |
CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
|
US20160032284A1
(en)
|
2011-09-02 |
2016-02-04 |
Arrowhead Research Corportation |
Organic compositions to treat hsf1-related diseases
|
SG11201401314PA
(en)
|
2011-09-07 |
2014-09-26 |
Marina Biotech Inc |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
CN104023713A
(en)
|
2011-09-07 |
2014-09-03 |
德国癌症研究中心 |
Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
|
CA2847888A1
(en)
|
2011-09-09 |
2013-03-14 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
AR087862A1
(en)
*
|
2011-09-13 |
2014-04-23 |
Monsanto Technology Llc |
METHODS AND COMPOSITIONS FOR WEED CONTROL
|
AU2012308737B2
(en)
*
|
2011-09-13 |
2018-06-14 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
EP2756085B1
(en)
*
|
2011-09-13 |
2019-03-20 |
Monsanto Technology LLC |
Methods and compositions for weed control
|
WO2013040021A1
(en)
*
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
WO2013043910A1
(en)
|
2011-09-20 |
2013-03-28 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
BR112014007569A2
(en)
|
2011-09-30 |
2017-04-18 |
Genentech Inc |
diagnostic methylation markers epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or tumor cells
|
EP2764369A1
(en)
|
2011-10-03 |
2014-08-13 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
|
PL2764101T3
(en)
|
2011-10-04 |
2017-09-29 |
Bayer Intellectual Property Gmbh |
RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE
|
US20150018383A1
(en)
|
2011-10-14 |
2015-01-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Biomarkers of renal disorders
|
AU2012322618A1
(en)
|
2011-10-14 |
2014-05-29 |
Genentech, Inc. |
Anti-HtrA1 antibodies and methods of use
|
EP3960726A1
(en)
|
2011-10-18 |
2022-03-02 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
US20140248284A1
(en)
|
2011-10-20 |
2014-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the detection and the treatment of cardiac remodeling
|
BR122020026845B1
(en)
|
2011-11-02 |
2021-04-13 |
Ceres, Inc |
METHOD OF INCREASING PLANT Yield IN SOIL CONTAINING HIGH LEVELS OF AL3 +, METHOD OF INCREASING TOLERANCE IN A PLANT
|
MX356814B
(en)
|
2011-11-03 |
2018-06-13 |
Quark Pharmaceuticals Inc |
Methods and compositions for neuroprotection.
|
JP6346093B2
(en)
|
2011-11-04 |
2018-06-20 |
アリスタ シリアル テクノロジーズ プロプライエタリー リミテッドArista Cereal Technologies Pty Ltd |
High amylose wheat
|
US20140286965A1
(en)
|
2011-11-07 |
2014-09-25 |
Inserm |
Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
|
WO2013070821A1
(en)
|
2011-11-08 |
2013-05-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
EP2782998B1
(en)
|
2011-11-22 |
2018-01-10 |
Novozymes Inc. |
Polypeptides having beta-xylosidase activity and polynucleotides encoding same
|
US20140328864A1
(en)
|
2011-11-22 |
2014-11-06 |
Inserm (Institut National De La Sente Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
BR112014012417A2
(en)
|
2011-12-01 |
2017-06-06 |
Novozymes Inc |
isolated polypeptide and polynucleotide, recombinant host cell, methods for producing a polypeptide, a mutant of a source cell, and a protein, and for inhibiting expression of a polypeptide, transgenic plant, part of the plant or cell of plant, rna molecule, processes for degrading or converting a cellulosic or xylan-containing material, to produce a fermentation product, and fermentation of a cellulosic or xylan-containing material, and integral broth formulation or cell culture composition
|
WO2013079533A1
(en)
|
2011-12-02 |
2013-06-06 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013079531A2
(en)
|
2011-12-02 |
2013-06-06 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
BR112014013853A2
(en)
|
2011-12-09 |
2020-01-14 |
Ceres Inc |
use of an isolated nucleic acid, method of obtaining a transgenic plant cell, method of obtaining a transgenic plant, method of producing a plant, method of producing biomass, method of biomass processing, method of altering the composition of biomass , biomass composition modulation method, production method of a forage product
|
UA116097C2
(en)
|
2011-12-11 |
2018-02-12 |
Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре |
Methods of modulating stomata conductance and plant expression constructs for executing same
|
DK2791330T3
(en)
|
2011-12-16 |
2017-11-06 |
Novozymes Inc |
Polypeptides with laccase activity and polynucleotides encoding them
|
WO2013096991A1
(en)
|
2011-12-27 |
2013-07-04 |
Commonwealth Scientific And Industrial Research Organisation |
Production of dihydrosterculic acid and derivatives thereof
|
CA2860432C
(en)
|
2011-12-27 |
2024-06-04 |
Commonwealth Scientific And Industrial Research Organisation |
Simultaneous gene silencing and suppressing gene silencing in the same cell
|
MX2014007964A
(en)
|
2011-12-27 |
2014-10-06 |
Commw Scient Ind Res Org |
Processes for producing lipids.
|
EP2798089B1
(en)
|
2011-12-30 |
2018-05-23 |
Bio-rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
US20130180008A1
(en)
|
2012-01-06 |
2013-07-11 |
Pioneer Hi Bred International Inc |
Ovule Specific Promoter and Methods of Use
|
CN104039819A
(en)
|
2012-01-06 |
2014-09-10 |
先锋国际良种公司 |
Compositions and methods for the expression of a sequence in a reproductive tissue of a plant
|
WO2013103365A1
(en)
|
2012-01-06 |
2013-07-11 |
Pioneer Hi-Bred International, Inc. |
Pollen preferred promoters and methods of use
|
AU2013208720A1
(en)
|
2012-01-09 |
2014-07-24 |
Arrowhead Research Corporation |
RNAi agents to treat Beta-Catenin related diseases
|
AU2013209279B2
(en)
|
2012-01-11 |
2017-12-14 |
North Carolina State University |
Method for modulating plant root architecture
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
MX344968B
(en)
|
2012-02-01 |
2017-01-12 |
Dow Agrosciences Llc |
Chloroplast transit peptide.
|
WO2013121034A1
(en)
|
2012-02-17 |
2013-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing adipose tissue inflammation
|
EP2817325B1
(en)
|
2012-02-20 |
2019-06-26 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US9663560B2
(en)
*
|
2012-02-28 |
2017-05-30 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Cotton PHYA1 RNAi improves fiber quality, root elongation, flowering, maturity and yield potential in Gossypium hirsutum L
|
EP2844248A1
(en)
|
2012-03-16 |
2015-03-11 |
F. Hoffmann-La Roche AG |
Methods of treating melanoma with pak1 inhibitors
|
PT2830662T
(en)
|
2012-03-29 |
2018-11-29 |
Univ Columbia |
Methods for treating hair loss disorders
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2650013A1
(en)
|
2012-04-10 |
2013-10-16 |
Deutsches Krebsforschungszentrum |
Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
|
IN2014KN02312A
(en)
|
2012-04-19 |
2015-05-01 |
Temasek Life Sciences Lab Ltd |
|
WO2013158966A1
(en)
|
2012-04-20 |
2013-10-24 |
Futuragene Israel Ltd. |
Bronze bug control agents
|
US20150082490A1
(en)
|
2012-04-23 |
2015-03-19 |
Futuragene Israel Ltd. |
Glycaspis Brimblecombei Control Agents
|
US9446102B2
(en)
|
2012-04-23 |
2016-09-20 |
Novozymes A/S |
Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same
|
EP2841570B1
(en)
|
2012-04-23 |
2017-12-20 |
Novozymes A/S |
Polypeptides having glucuronyl esterase activity and polynucleotides encoding same
|
WO2013159149A1
(en)
|
2012-04-25 |
2013-10-31 |
Commonwealth Scientific And Industrial Research Organisation |
High oleic acid oils
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2013164444A1
(en)
|
2012-05-03 |
2013-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
|
US20150126573A1
(en)
|
2012-05-09 |
2015-05-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
JP2015520373A
(en)
|
2012-05-22 |
2015-07-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Method for diagnosing and treating focal segmental glomerulosclerosis
|
SI2858647T1
(en)
|
2012-06-08 |
2018-11-30 |
Sensorion |
H4 receptor inhibitors for treating tinnitus
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
WO2013192545A1
(en)
|
2012-06-22 |
2013-12-27 |
The Regents Of The University Of California |
Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants
|
US20150204851A1
(en)
|
2012-06-27 |
2015-07-23 |
Metanomics Health Gmbh |
Methods for identifying diabetes drugs
|
WO2014006025A2
(en)
|
2012-07-02 |
2014-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Marker of pathogenicity in salmonella
|
US20150184155A1
(en)
*
|
2012-07-18 |
2015-07-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for preventing and treating chronic kidney disease (ckd)
|
DK2877494T3
(en)
|
2012-07-23 |
2020-09-21 |
La Jolla Inst Allergy & Immunology |
PTPRS and proteoglycans in autoimmune disease
|
JP6431480B2
(en)
|
2012-08-31 |
2018-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
Biotin conjugates for the treatment and diagnosis of Alzheimer's disease
|
EP2897633B1
(en)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
WO2014046983A1
(en)
|
2012-09-21 |
2014-03-27 |
Intensity Therapeutic |
Method of treating cancer
|
US20150259701A1
(en)
*
|
2012-10-03 |
2015-09-17 |
Futuragene Israel Ltd. |
Gall wasp control agents
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
WO2014053871A1
(en)
|
2012-10-04 |
2014-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for screening a compound capable of inhibiting the notch1 transcriptional activity
|
CN104781403A
(en)
|
2012-10-05 |
2015-07-15 |
株式会社百奥尼 |
Amphiregulin-specific double-helical oligo-RNA, double-helical oligo-RNA structure comprising double-helical oligo-RNA, and composition for preventing or treating respiratory diseases containing same
|
DK2903412T3
(en)
|
2012-10-08 |
2019-12-16 |
Novozymes As |
Polypeptides with cellulolysis enhancing activity and polynucleotides encoding them
|
ES2776029T3
(en)
|
2012-10-08 |
2020-07-28 |
St Jude Childrens Res Hospital |
Therapies based on the control of the stability and function of regulatory T cells by means of a neuropilin-1 axis: semaphorin
|
US20150259403A1
(en)
|
2012-10-10 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and Pharmaceutical Compositions for Treatment of Gastrointestinal Stromal Tumors
|
US20140109259A1
(en)
|
2012-10-11 |
2014-04-17 |
Pioneer Hi Bred International Inc |
Guard Cell Promoters and Uses Thereof
|
US9499801B2
(en)
|
2012-10-12 |
2016-11-22 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
WO2014056917A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
EP2906689B1
(en)
|
2012-10-12 |
2018-12-12 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9404094B2
(en)
|
2012-10-12 |
2016-08-02 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
WO2014056921A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9453207B2
(en)
|
2012-10-12 |
2016-09-27 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
WO2014056916A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
AU2013336237A1
(en)
|
2012-10-22 |
2015-06-11 |
Sabag-Rfa Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
IN2015DN03795A
(en)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
US20150275194A1
(en)
|
2012-10-24 |
2015-10-01 |
Novozymes A/S |
Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
|
US20150246118A1
(en)
|
2012-10-26 |
2015-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
WO2014064192A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
WO2014072416A1
(en)
|
2012-11-08 |
2014-05-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
EP2732815A1
(en)
|
2012-11-16 |
2014-05-21 |
Neurochlore |
Modulators of intracellular chloride concentration for treating fragile X syndrome
|
WO2014090765A1
(en)
|
2012-12-12 |
2014-06-19 |
Bayer Cropscience Ag |
Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops
|
US9486473B2
(en)
|
2012-12-13 |
2016-11-08 |
Ymir Genomics, Llc |
MicroRNAs and uses thereof
|
AU2013358981A1
(en)
|
2012-12-14 |
2015-06-04 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2014091466A2
(en)
|
2012-12-14 |
2014-06-19 |
Indian Agricultural Research Institute |
A method for the control of nematodes in plants
|
US20150337280A1
(en)
|
2012-12-19 |
2015-11-26 |
Novozymes A/S |
Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
|
CA2891855A1
(en)
|
2012-12-21 |
2014-06-26 |
Sykehuset Sorlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
BR112015014624A2
(en)
|
2012-12-24 |
2017-10-10 |
Novozymes As |
isolated polypeptide, composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and method for textile treatment
|
US10258682B2
(en)
|
2013-01-16 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
WO2014118317A1
(en)
|
2013-02-01 |
2014-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
AU2014212081A1
(en)
|
2013-02-04 |
2015-08-13 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
WO2014122199A1
(en)
|
2013-02-06 |
2014-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of chronic intestinal pseudo-obstruction
|
EP2767594A1
(en)
|
2013-02-19 |
2014-08-20 |
Deutsches Krebsforschungszentrum |
The signature of Wnt/ß-catenin signaling in Cancer
|
WO2014128127A1
(en)
|
2013-02-19 |
2014-08-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of prostate cancer
|
JP6255038B2
(en)
|
2013-02-26 |
2017-12-27 |
トリアクト セラピューティクス,インク. |
Cancer treatment
|
CN105143470B
(en)
|
2013-02-28 |
2020-06-09 |
德克萨斯大学系统董事会 |
Methods for classifying cancer as susceptible to TMEPAI-directed therapy and treating the cancer
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
EA030650B1
(en)
|
2013-03-08 |
2018-09-28 |
Новартис Аг |
Lipids and lipid compositions for the delivery of active agents
|
US9273322B2
(en)
|
2013-03-12 |
2016-03-01 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
US9243258B2
(en)
|
2013-03-12 |
2016-01-26 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
DK2968424T3
(en)
|
2013-03-13 |
2020-03-30 |
Geneweave Biosciences Inc |
Non-replicative transduction particles and transduction particle-based reporter systems
|
WO2014140165A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
|
WO2014140167A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
JP6566933B2
(en)
|
2013-03-15 |
2019-08-28 |
サッター ベイ ホスピタルズ |
FALZ for use as a target for therapy to treat cancer
|
US9546364B2
(en)
|
2013-03-15 |
2017-01-17 |
Carnegie Mellon University |
Synthetic lariat RNA for RNA interference
|
EP2971077B1
(en)
|
2013-03-15 |
2019-05-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
|
EP2968551B1
(en)
|
2013-03-15 |
2021-05-05 |
The Trustees of Columbia University in the City of New York |
Fusion proteins and methods thereof
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014170712A1
(en)
|
2013-04-15 |
2014-10-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rac-1 inhibitors or pi3k inhibitors for preventing intestinal barrier dysfunction
|
EP2986287A2
(en)
|
2013-04-18 |
2016-02-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof
|
WO2014184683A2
(en)
|
2013-04-26 |
2014-11-20 |
Oslo Universitetssykehus Hf |
Compositions and methods for targeting antigen-presenting cells
|
EP2810952A1
(en)
|
2013-06-03 |
2014-12-10 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Novel pest control methods
|
AU2014280852B2
(en)
|
2013-06-13 |
2017-11-09 |
Commonwealth Scientific And Industrial Research Organisation |
Barley with very low levels of hordeins
|
US10155001B2
(en)
|
2013-06-14 |
2018-12-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
RAC1 inhibitors for inducing bronchodilation
|
WO2014203189A1
(en)
|
2013-06-18 |
2014-12-24 |
Rosetta Genomics Ltd. |
Nanocarrier system for micrornas and uses thereof
|
EP3682873B1
(en)
|
2013-06-25 |
2024-06-12 |
The Walter and Eliza Hall Institute of Medical Research |
Smac mimetics for use in the treatment of persistent hiv infection
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
WO2015001053A1
(en)
|
2013-07-03 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the screening of substances that may be useful for the prevention and treatment of infections by enterobacteriaceae family
|
BR112015033053A2
(en)
|
2013-07-03 |
2018-03-20 |
Hope City |
cancer treatment method in a subject, method of stimulating the immune system in a subject, method of increasing the distribution of an anticancer agent to a tumor cell, composition, and kit
|
ES2776353T3
(en)
|
2013-07-17 |
2020-07-30 |
Univ Columbia |
Novel Phosphodiesterase Inhibitors and Uses Thereof
|
WO2015015498A1
(en)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
WO2015015496A1
(en)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
EP2835423A1
(en)
|
2013-08-09 |
2015-02-11 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Ligase E3 RNF185 inhibitors and uses thereof
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
BR112016005541A2
(en)
|
2013-09-11 |
2018-01-30 |
Du Pont |
recombinant nucleic acid molecule, dna construct, transgenic plant, transgenic plant seed
|
EP3046564B1
(en)
|
2013-09-16 |
2024-05-22 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Inhibitor of the gluk2/gluk5 receptor expression for use in the treatment of epilepsy
|
US20160250249A1
(en)
|
2013-10-03 |
2016-09-01 |
Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) |
Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
CA2925129C
(en)
|
2013-10-04 |
2023-04-04 |
Novartis Ag |
3' end caps for rnai agents for use in rna interference
|
CN105792832B
(en)
|
2013-10-04 |
2021-03-23 |
诺华股份有限公司 |
Organic compounds for the treatment of hepatitis B virus
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
MX2016004573A
(en)
|
2013-10-11 |
2016-07-21 |
Genentech Inc |
Nsp4 inhibitors and methods of use.
|
EP3057434A4
(en)
|
2013-10-16 |
2017-05-03 |
The Australian National University |
Method for modulating plant growth
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
JP6633532B2
(en)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
Optimal corn loci
|
EP3066110B1
(en)
|
2013-11-04 |
2021-12-29 |
Corteva Agriscience LLC |
Optimal maize loci
|
UA121459C2
(en)
|
2013-11-04 |
2020-06-10 |
Дау Агросаєнсиз Елелсі |
Optimal soybean loci
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
CA2965327C
(en)
|
2013-11-08 |
2023-05-09 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
EP3068407A1
(en)
|
2013-11-11 |
2016-09-21 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
|
EP3068440B1
(en)
|
2013-11-15 |
2020-01-08 |
Northwestern University |
Inhibition of oxidative stress in atrial fibrillation
|
EP3074513A1
(en)
|
2013-11-26 |
2016-10-05 |
Novozymes A/S |
Enzyme compositions and uses thereof
|
ES2711882T3
(en)
|
2013-11-28 |
2019-05-08 |
B Creative Sweden Ab |
Method of treatment of diabetic nephropathy
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
WO2015089338A2
(en)
|
2013-12-11 |
2015-06-18 |
Sloan-Kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
CN105979965B
(en)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
Method of treating wounds
|
PL3083556T3
(en)
|
2013-12-19 |
2020-06-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP4019506A1
(en)
|
2013-12-19 |
2022-06-29 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
JP6490077B2
(en)
|
2013-12-20 |
2019-03-27 |
フォンダツィオーネ・イスティトゥート・イタリアーノ・ディ・テクノロジャFondazione Istituto Italiano Di Tecnologia |
Modulator of intracellular chloride concentration for treating Down's syndrome
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
JP6372930B2
(en)
|
2013-12-27 |
2018-08-15 |
国立大学法人高知大学 |
Malignant tumor treatment
|
TW201527314A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527313A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527312A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527316A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
RU2016132574A
(en)
|
2014-01-09 |
2018-02-12 |
Интра-Селлулар Терапиз, Инк. |
ORGANIC COMPOUNDS
|
US10100313B2
(en)
|
2014-02-10 |
2018-10-16 |
Institut Curie |
Use of Mcoln-1 modulators to regulate cell migration
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
KR102228828B1
(en)
|
2014-03-11 |
2021-03-16 |
셀렉티스 |
Method for generating t-cells compatible for allogenic transplantation
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
CN110846316B
(en)
|
2014-03-25 |
2023-10-31 |
阿克丘勒斯治疗公司 |
UNA oligomers with reduced off-target effects in gene silencing
|
JP6771387B2
(en)
|
2014-03-25 |
2020-10-21 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
Transthyretin allele-selective UNA oligomer for gene silencing
|
JP6426268B2
(en)
|
2014-04-04 |
2018-11-21 |
バイオニア コーポレーションBioneer Corporation |
Novel double helix oligo RNA and pharmaceutical composition for preventing or treating fibrosis or respiratory disease comprising the same
|
EP3131569B1
(en)
|
2014-04-16 |
2020-05-27 |
Philippe Rouet |
Apoo for use in a method for treating cancer and various pathophysiological situations
|
EP2932969A1
(en)
|
2014-04-17 |
2015-10-21 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Pancreatic cancer therapy and diagnosis
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
US9101100B1
(en)
|
2014-04-30 |
2015-08-11 |
Ceres, Inc. |
Methods and materials for high throughput testing of transgene combinations
|
US9545417B2
(en)
|
2014-05-01 |
2017-01-17 |
The Johns Hopkins University |
Methods of inhibiting cancer stem cells with HMGA1 inhibitors
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
KR101633881B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating dopamine-dependent disorders
|
KR101633876B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating affective and addictive disorders
|
DK3152315T3
(en)
|
2014-06-06 |
2018-11-26 |
Novozymes As |
ENZYME COMPOSITIONS AND APPLICATIONS THEREOF
|
CN106460022B
(en)
|
2014-06-24 |
2018-06-05 |
加州大学董事会 |
The production method of xyloside xylitol oligomer
|
EP2966157B1
(en)
|
2014-07-07 |
2023-11-01 |
Nuseed Global Innovation Ltd |
Processes for producing industrial products from plant lipids
|
ES2718042T3
(en)
|
2014-07-09 |
2019-06-27 |
Inst Nat Sante Rech Med |
Methods and compositions for the treatment of neuropathic pain
|
US10480000B2
(en)
|
2014-07-15 |
2019-11-19 |
Ceres, Inc. |
Methods of increasing crop yield under abiotic stress
|
US10342761B2
(en)
|
2014-07-16 |
2019-07-09 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
EP3741375A1
(en)
|
2014-07-17 |
2020-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating neuromuscular junction-related diseases
|
WO2016022947A1
(en)
|
2014-08-07 |
2016-02-11 |
The Johns Hopkins University |
Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
|
US20170218384A1
(en)
|
2014-08-08 |
2017-08-03 |
Pioneer Hi-Bred International, Inc. |
Ubiquitin promoters and introns and methods of use
|
CN107427552B
(en)
|
2014-08-22 |
2022-12-20 |
广州英恩迈生物医药科技有限公司 |
Methods and compositions for the prevention and treatment of diseases or conditions associated with abnormal levels and/or activity of the IFP35 protein family
|
CN114010788A
(en)
|
2014-08-22 |
2022-02-08 |
奥克兰联合服务有限公司 |
Channel modulators
|
EP3188760B1
(en)
|
2014-09-05 |
2023-12-06 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
EP3188799B1
(en)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
EP3188746B1
(en)
|
2014-09-05 |
2024-06-19 |
The Johns Hopkins University |
Targeting capn9 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
EP3194581A4
(en)
|
2014-09-15 |
2018-04-25 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
JP6898848B2
(en)
|
2014-09-19 |
2021-07-07 |
メモリアル スローン ケタリング キャンサー センター |
Methods for treating brain metastases
|
CA2962406A1
(en)
|
2014-09-25 |
2016-03-31 |
Cold Spring Harbor Laboratory |
Treatment of rett syndrome
|
EP3197446A2
(en)
|
2014-09-26 |
2017-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
|
WO2016050680A1
(en)
|
2014-09-29 |
2016-04-07 |
Novozymes A/S |
Yoqm-inactivation in bacillus
|
US9705501B2
(en)
*
|
2014-10-01 |
2017-07-11 |
Maxim Integrated Products, Inc. |
Systems and methods for enhancing confidentiality via logic gate encryption
|
EP3009147A1
(en)
|
2014-10-16 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant glioblastoma
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
EP3209775A4
(en)
|
2014-10-22 |
2018-09-12 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
WO2016066671A1
(en)
|
2014-10-29 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant cancers using progastrin inhibitors
|
CA2974716A1
(en)
|
2014-11-12 |
2016-05-19 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
EP3229842B1
(en)
|
2014-12-08 |
2022-07-06 |
The Board of Regents of The University of Texas System |
Lipocationic polymers and uses thereof
|
JP7105065B2
(en)
|
2014-12-15 |
2022-07-22 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッド |
Ligand-modified double-stranded nucleic acid
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
EP3778644A3
(en)
|
2014-12-23 |
2021-06-02 |
The Trustees of Columbia University in the City of New York |
Fgfr-tacc fusion proteins and methods thereof
|
KR102360028B1
(en)
*
|
2014-12-26 |
2022-02-08 |
삼성전자주식회사 |
Composition for reducing senescence of a cell or a subject comprising Smurf2 inhibitor and use thereof
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
US9434947B2
(en)
*
|
2015-01-20 |
2016-09-06 |
Oregon Health & Science University |
Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
|
WO2016128523A1
(en)
|
2015-02-12 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
WO2016131944A1
(en)
|
2015-02-20 |
2016-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cardiovascular diseases
|
CA2978449A1
(en)
|
2015-03-02 |
2016-09-09 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an il-33 antagonist
|
MA41629A
(en)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
|
WO2016139331A1
(en)
|
2015-03-05 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of melanoma
|
WO2016145005A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticles for brain tumor treatment
|
CN107429251A
(en)
|
2015-03-09 |
2017-12-01 |
肯塔基大学研究基金会 |
For treating the miRNA of breast cancer
|
US10781446B2
(en)
|
2015-03-09 |
2020-09-22 |
University Of Kentucky Research Foundation |
RNA nanoparticle for treatment of gastric cancer
|
WO2016142427A1
(en)
|
2015-03-10 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method ank kit for reprogramming somatic cells
|
EP3268027B1
(en)
|
2015-03-13 |
2022-11-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Hepcidin antagonists for use in the treatment of inflammation
|
KR101797569B1
(en)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
Liver Targeting Metal Nano-particle Based Nucleic Acid Delivery System And Manufacturing Method Thereof
|
WO2016161299A1
(en)
|
2015-04-01 |
2016-10-06 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
EP3078378B1
(en)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Use of factor xa inhibitors for regulating glycemia
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
US10828381B2
(en)
|
2015-04-17 |
2020-11-10 |
University Of Kentucky Research Foundation |
RNA nanoparticles and method of use thereof
|
EP3085785A1
(en)
|
2015-04-22 |
2016-10-26 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
|
EP3286221A1
(en)
|
2015-04-22 |
2018-02-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
WO2016170382A1
(en)
|
2015-04-23 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
US20180148793A1
(en)
|
2015-05-19 |
2018-05-31 |
Fred Hutchinson Cancer Research Center |
Biomarkers and uses thereof for selecting pancreas cancer intervention
|
EP3297615A1
(en)
|
2015-05-20 |
2018-03-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016191734A1
(en)
|
2015-05-28 |
2016-12-01 |
University Of California Berkeley |
Monofunctional aldehyde and alcohol dehydrogenases for production of fuels and commodity chemicals
|
CN107920488B
(en)
|
2015-05-29 |
2022-06-21 |
阿凯笛亚生物科学公司 |
Reduced gluten cereal grain and compositions thereof
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
CN107922480B
(en)
|
2015-06-12 |
2022-09-23 |
艾利妥 |
anti-CD 33 antibodies and methods of use thereof
|
EP3310921B8
(en)
|
2015-06-17 |
2023-03-15 |
Corteva Agriscience LLC |
Plant regulatory elements and methods of use thereof
|
EP3313420B1
(en)
|
2015-06-25 |
2024-03-13 |
The Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
JP6983752B2
(en)
|
2015-07-06 |
2021-12-17 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
Nucleic acid molecule targeting superoxide dismutase 1 (SOD1)
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
WO2017013270A1
(en)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
MX2018002090A
(en)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof.
|
KR20180054639A
(en)
|
2015-08-28 |
2018-05-24 |
알렉터 엘엘씨 |
Anti-SIGLEC-7 Antibodies and Methods of Use Thereof
|
CN108368507B
(en)
|
2015-09-02 |
2022-03-22 |
阿尔尼拉姆医药品有限公司 |
iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
|
US11236346B2
(en)
|
2015-09-04 |
2022-02-01 |
Keygene N.V. |
Diplospory gene
|
MA44908A
(en)
*
|
2015-09-08 |
2018-07-18 |
Sylentis Sau |
ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
|
EP3702470A3
(en)
|
2015-09-09 |
2020-10-07 |
The Trustees of Columbia University in the City of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
JP7041616B2
(en)
|
2015-09-14 |
2022-03-24 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
Lipocationic dendrimer and its use
|
US10086063B2
(en)
|
2015-09-23 |
2018-10-02 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
US10383935B2
(en)
|
2015-09-23 |
2019-08-20 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-07-04 |
Amgen Inc. |
ASGR inhibitors
|
WO2017059113A1
(en)
|
2015-09-29 |
2017-04-06 |
Duke University |
Compositions and methods for identifying and treating dystonia disorders
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
JP2018531037A
(en)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
US10421821B2
(en)
|
2015-10-30 |
2019-09-24 |
Genentech, Inc. |
Anti-HtrA1 antibodies and methods of use thereof
|
AU2016355920B2
(en)
|
2015-11-18 |
2020-11-12 |
Commonwealth Scientific And Industrial Research Organisation |
Rice grain with thickened aleurone
|
WO2017085566A1
(en)
|
2015-11-20 |
2017-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increase/induction of immune responses
|
CN115109850A
(en)
|
2015-11-30 |
2022-09-27 |
谢彦晖 |
Use of AKT2 in diagnosis and treatment of tumors
|
US10583171B2
(en)
|
2015-11-30 |
2020-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
NMDAR antagonists for the treatment of diseases associated with angiogenesis
|
US10995339B2
(en)
|
2015-11-30 |
2021-05-04 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
US20180353486A1
(en)
|
2015-12-01 |
2018-12-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of darier disease
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
EP3386519B1
(en)
|
2015-12-13 |
2021-03-24 |
Nitto Denko Corporation |
Sirna structures for high activity and reduced off target
|
GB201522186D0
(en)
|
2015-12-16 |
2016-01-27 |
Singapore Health Services Pte Ltd And Nat University Of Singapore The |
Treatment of fibrosis
|
EP3394268B1
(en)
|
2015-12-22 |
2023-07-19 |
Pioneer Hi-Bred International, Inc. |
Tissue-preferred promoters and methods of use
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
CN109069520A
(en)
|
2016-02-25 |
2018-12-21 |
应用生物实验室公司 |
Protect the composition and method of airborne pathogen and stimulant
|
EP3423568A4
(en)
|
2016-03-04 |
2019-11-13 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
|
DK3429603T3
(en)
|
2016-03-15 |
2022-03-14 |
Childrens Medical Center |
PROCEDURES AND COMPOSITIONS FOR EXPANSION OF HEMATOPOETIC STEM CELLS
|
HRP20220335T1
(en)
|
2016-03-15 |
2022-05-13 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
EP3432911A1
(en)
|
2016-03-23 |
2019-01-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the neuronal calcium sensor 1 for treating wolfram syndrome
|
US11525140B2
(en)
|
2016-03-24 |
2022-12-13 |
Universiteit Leiden |
Methods for transfecting plants and for reducing random integration events
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
MA45469A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
|
MA45470A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
KRAS NUCLEIC ACIDS AND THEIR USES
|
MA45328A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
MA45349A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
EGFR NUCLEIC ACIDS AND THEIR USES
|
WO2017182834A1
(en)
|
2016-04-19 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating resistant glioblastoma
|
US10550398B2
(en)
|
2016-04-19 |
2020-02-04 |
Novozymes A/S |
RlmA-inactivated filamentous fungal host cell
|
EP3448369A4
(en)
|
2016-04-29 |
2020-01-01 |
The Regents of The University of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
CR20180589A
(en)
|
2016-05-13 |
2019-02-27 |
4D Molecular Therapeutics Inc |
VARIANT CAPSULES OF ADENOASOCIATED VIRUSES AND METHODS OF USE OF THESE
|
CA3024129A1
(en)
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
WO2017202813A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
PT109454A
(en)
|
2016-06-14 |
2017-12-14 |
Phyzat Biopharmaceuticals Lda |
NUCLEIC ACIDS OF INTERFERENCE AND COMPOSITIONS THAT UNDERSTAND THEM
|
WO2017216352A1
(en)
|
2016-06-16 |
2017-12-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut inflammatory diseases such as inflammatory bowel diseases (ibd) or irritable bowel syndrome (ibs)
|
UA127388C2
(en)
|
2016-06-24 |
2023-08-09 |
Піонір Хай-Бред Інтернешнл, Інк. |
Plant regulatory elements and methods of use thereof
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
AU2017291727B2
(en)
|
2016-07-05 |
2021-07-08 |
California Institute Of Technology |
Fractional initiator hybridization chain reaction
|
JP6371486B2
(en)
*
|
2016-07-08 |
2018-08-08 |
TAK−Circulator株式会社 |
Interleukin 6, Interleukin 13, TNF, G-CSF, CXCL1, CXCL2, CXCL2, Method for screening for preventive or therapeutic agent for diseases, and Interleukin 6, Interleukin 13, TNF, G-CSF, CXCL1 , CXCL2 or CXCL5 preventive or therapeutic agent for diseases caused by CXCL5
|
WO2018008749A1
(en)
|
2016-07-08 |
2018-01-11 |
TAK-Circulator株式会社 |
Nucleic acid inhibiting expression of the mex3b gene, mex3b gene expression inhibitor, method for inhibiting mex3b gene expression, and prophylactic or therapeutic agent for disease caused by mex3b gene expression
|
CN109890965A
(en)
|
2016-07-19 |
2019-06-14 |
匹兹堡大学联邦系统高等教育 |
Target the oncolytic virus of STAT3
|
WO2018019843A1
(en)
|
2016-07-26 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
|
JP2019528437A
(en)
|
2016-07-28 |
2019-10-10 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Method for treating cancer diseases by targeting tumor-associated macrophages
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
US20190183114A1
(en)
|
2016-08-05 |
2019-06-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for the preservationof organs
|
CA3034617A1
(en)
|
2016-08-30 |
2018-03-08 |
California Institute Of Technology |
Immunohistochemistry via hybridization chain reaction
|
US20190242908A1
(en)
|
2016-09-08 |
2019-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
US10933081B2
(en)
|
2016-09-21 |
2021-03-02 |
Alnylam Pharmaceuticals, Inc. |
Myostatin iRNA compositions and methods of use thereof
|
EP3516071B1
(en)
|
2016-09-22 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of lung cancer
|
SG10201912574WA
(en)
|
2016-09-28 |
2020-02-27 |
Blade Therapeutics Inc |
Calpain modulators and therapeutic uses thereof
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
EP3318277A1
(en)
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
EP3538102A4
(en)
|
2016-11-10 |
2020-06-24 |
Memorial Sloan-Kettering Cancer Center |
Inhibition of kmt2d for the treatment of cancer
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
US20190276833A1
(en)
|
2016-11-17 |
2019-09-12 |
Deutsches Krebsforschungszentrum |
Cancer treatment by glycerol-3-phosphate dehydrogenase 1 inhibition
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
WO2018104909A2
(en)
|
2016-12-09 |
2018-06-14 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
BR112019012062A2
(en)
|
2016-12-14 |
2019-11-12 |
Progenity Inc |
treating a gastrointestinal tract disease with a jak inhibitor and devices
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
EP3554343A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
EP3554342A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
US11134889B2
(en)
|
2016-12-14 |
2021-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
|
KR20190095936A
(en)
|
2016-12-14 |
2019-08-16 |
프로제너티, 인크. |
Treatment of Gastrointestinal Diseases with Integrin Inhibitors
|
MX2019006823A
(en)
|
2016-12-14 |
2019-10-21 |
Progenity Inc |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device.
|
WO2018109222A1
(en)
|
2016-12-16 |
2018-06-21 |
Universite de Bordeaux |
Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
|
WO2018115083A1
(en)
|
2016-12-21 |
2018-06-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
|
WO2018115477A1
(en)
|
2016-12-23 |
2018-06-28 |
Universite De Strasbourg |
Dynamin 2 inhibitor for the treatment of myotonic dystrophy
|
US20230190958A1
(en)
|
2017-01-13 |
2023-06-22 |
Jichi Medical University |
AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
|
WO2018134386A1
(en)
|
2017-01-23 |
2018-07-26 |
Novozymes A/S |
Host cells and methods for producing double-stranded rna
|
WO2018138106A1
(en)
|
2017-01-27 |
2018-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of heart failure
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
CN110546265A
(en)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
WO2018162676A1
(en)
|
2017-03-08 |
2018-09-13 |
Université De Strasbourg |
DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
WO2018172155A1
(en)
|
2017-03-23 |
2018-09-27 |
Novozymes A/S |
Improved filamentous fungal host cells
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
CA3054632A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
CA3054159A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
WO2018189335A1
(en)
|
2017-04-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
US20210283068A1
(en)
|
2017-04-19 |
2021-09-16 |
St. Jude Children's Research Hospital |
Tumor suppression by modulation of non-canonical autophagy (lap) in myeloid cells
|
CN106942162A
(en)
*
|
2017-04-25 |
2017-07-14 |
遵义医学院 |
A kind of device and its application method suitable for white backed planthopper feeding method RNA interference experiments
|
WO2018201144A1
(en)
|
2017-04-28 |
2018-11-01 |
Precision Biosciences, Inc. |
Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
|
CA3061738A1
(en)
|
2017-04-28 |
2018-11-01 |
Auckland Uniservices Limited |
Methods of treatment and novel constructs
|
EP4029943A1
(en)
|
2017-05-08 |
2022-07-20 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
WO2018213933A1
(en)
|
2017-05-25 |
2018-11-29 |
The Governors Of The University Of Alberta |
Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
|
EP3412288A1
(en)
|
2017-06-08 |
2018-12-12 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating acne
|
CN111032025A
(en)
|
2017-06-20 |
2020-04-17 |
居里研究所 |
Use of an inhibitor of SUV39H1 histone methyltransferase in the combination therapy of cancer
|
ES2871400T3
(en)
|
2017-06-20 |
2021-10-28 |
Inst Nat Sante Rech Med |
Immune cells deficient in SUV39H1
|
WO2018234538A1
(en)
|
2017-06-23 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Dhodh inhibitor and chk1 inhibitor for treating cancer
|
MA47691A
(en)
|
2017-08-03 |
2020-01-08 |
Alector Llc |
ANTI-CD33 ANTIBODIES AND PROCESSES FOR USE
|
EP3444347A1
(en)
|
2017-08-18 |
2019-02-20 |
Universität Heidelberg |
Use of anti-crispr polypeptides for specific activation of cas nucleases
|
EP3680334A4
(en)
|
2017-09-07 |
2021-09-22 |
Beijing Tide Pharmaceutical Co., Ltd. |
Double-stranded rna molecule targeting ckip-1 and use thereof
|
CR20200165A
(en)
|
2017-09-20 |
2020-06-05 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
AU2018337756A1
(en)
|
2017-09-25 |
2020-04-02 |
Pioneer Hi-Bred, International, Inc. |
Tissue-preferred promoters and methods of use
|
US20200237864A1
(en)
|
2017-10-10 |
2020-07-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating fibrotic interstitial lung disease
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Magnetic nanoparticles for the treatment of cancer
|
EP3701027A1
(en)
|
2017-10-26 |
2020-09-02 |
Les Laboratoires Servier SAS |
Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
|
SG11202003082UA
(en)
|
2017-11-13 |
2020-05-28 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
WO2019096787A1
(en)
|
2017-11-14 |
2019-05-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof
|
US20200352913A1
(en)
|
2017-11-23 |
2020-11-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
CN111770999A
(en)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
WO2019108835A1
(en)
|
2017-11-29 |
2019-06-06 |
The Trustees Of Columbia University In The City Of New York |
Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
KR102443358B1
(en)
|
2017-12-06 |
2022-09-14 |
어비디티 바이오사이언시스 인크. |
Compositions and methods for treating muscular dystrophy and myotonic dystrophy
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
EP3502259A1
(en)
|
2017-12-19 |
2019-06-26 |
Universiteit Leiden |
A combinational strategy for reducing random integration events when transfecting plants
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
CN111819285A
(en)
|
2018-01-09 |
2020-10-23 |
希博斯美国有限公司 |
Breakage-proof genes and mutations
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
US20210363587A1
(en)
|
2018-02-07 |
2021-11-25 |
St. Jude Children's Research Hospital |
EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
EP3762105A1
(en)
|
2018-03-06 |
2021-01-13 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
CN112105731A
(en)
|
2018-03-30 |
2020-12-18 |
日内瓦大学 |
micro-RNA expression constructs and uses thereof
|
WO2019199673A1
(en)
|
2018-04-09 |
2019-10-17 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
BR112020023800A2
(en)
|
2018-05-22 |
2021-02-23 |
Pioneer Hi-Bred International, Inc. |
plant regulatory elements and methods of using them
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
WO2019246455A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
WO2019246273A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
CA3097915A1
(en)
|
2018-06-28 |
2020-01-02 |
Pioneer Hi-Bred International, Inc. |
Methods for selecting transformed plants
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
JP2021531027A
(en)
|
2018-07-27 |
2021-11-18 |
アレクトル エルエルシー |
Anti-Siglec-5 antibody and how to use it
|
WO2020026968A1
(en)
|
2018-07-30 |
2020-02-06 |
株式会社遺伝子治療研究所 |
Method for enhancing gene expression by aav vector
|
WO2020033938A1
(en)
*
|
2018-08-10 |
2020-02-13 |
City Of Hope |
Programmable conditional sirnas and uses thereof
|
WO2020049026A1
(en)
|
2018-09-05 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating asthma and allergic diseases
|
WO2020061381A1
(en)
|
2018-09-19 |
2020-03-26 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
WO2020074502A1
(en)
|
2018-10-09 |
2020-04-16 |
Novozymes A/S |
Modified filamentous fungal host cell
|
EP3866807A1
(en)
|
2018-10-16 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Use of akt inhibitors in ophthalmology
|
WO2020079164A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
JP2022509018A
(en)
|
2018-10-31 |
2022-01-20 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ |
Biomarkers and usage for radiation-induced lung injury
|
CA3111090A1
(en)
|
2018-10-31 |
2020-05-07 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods for ochrobactrum-mediated plant transformation
|
EP3873455A1
(en)
|
2018-10-31 |
2021-09-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method for treating t-helper type 2 mediated disease
|
EP3650040A1
(en)
|
2018-11-07 |
2020-05-13 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating atopic dermatitis
|
US11708575B2
(en)
|
2018-11-16 |
2023-07-25 |
Nitto Denko Corporation |
RNA interference delivery formulation and methods for malignant tumors
|
US20220025423A1
(en)
|
2018-11-28 |
2022-01-27 |
Novozymes A/S |
Modified Filamentous Fungal Host Cells
|
US11883401B2
(en)
|
2019-01-08 |
2024-01-30 |
Duke University |
Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
|
EP3911957A1
(en)
|
2019-01-17 |
2021-11-24 |
F. Hoffmann-La Roche AG |
E3 ubiquitin ligase (ube3a) protein targets
|
TW202043276A
(en)
|
2019-01-21 |
2020-12-01 |
新加坡商新加坡保健服務私人有限公司 |
Treatment of hepatotoxicity
|
CA3125818A1
(en)
|
2019-02-01 |
2020-08-06 |
Universitat Basel |
Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
WO2020163705A1
(en)
|
2019-02-08 |
2020-08-13 |
Board Of Regents, The University Of Texas System |
Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
GB201902419D0
(en)
|
2019-02-22 |
2019-04-10 |
Singapore Health Serv Pte Ltd |
Treatment of kidney injury
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
AU2020234553A1
(en)
|
2019-03-11 |
2021-07-01 |
Pioneer Hi-Bred International, Inc. |
Methods for clonal plant production
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
US20220170033A1
(en)
|
2019-03-27 |
2022-06-02 |
Pioneer Hi-Bred International, Inc. |
Plant explant transformation
|
CA3127173A1
(en)
|
2019-03-28 |
2020-10-01 |
Pioneer Hi-Bred International, Inc. |
Modified agrobacterium strains and use thereof for plant transformation
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
AU2020259143A1
(en)
|
2019-04-19 |
2021-11-11 |
Assistance Publique Hopitaux De Paris |
pl6INK4a inhibitor for preventing or treating Huntington's disease
|
MX2021013356A
(en)
|
2019-05-03 |
2022-03-11 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of metabolic diseases.
|
GB201906291D0
(en)
|
2019-05-03 |
2019-06-19 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of metabolic diseases
|
EP3969472A1
(en)
|
2019-05-16 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
WO2020249769A1
(en)
|
2019-06-14 |
2020-12-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
|
US11473086B2
(en)
|
2019-06-19 |
2022-10-18 |
Ut-Battelle, Llc |
Loss of function alleles of PtEPSP-TF and its regulatory targets in rice
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
US20220265853A1
(en)
|
2019-07-12 |
2022-08-25 |
Gene Therapy Research Institution Co., Ltd. |
Adeno-associated virus virion for gene transfer to human liver
|
WO2021018783A1
(en)
|
2019-07-26 |
2021-02-04 |
Novozymes A/S |
Modified filamentous fungal host cell
|
WO2021019536A1
(en)
|
2019-07-30 |
2021-02-04 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
|
JP2022545376A
(en)
|
2019-08-14 |
2022-10-27 |
ヴァナリックス エスエー |
Method for in vitro production of hyaline cartilage tissue
|
WO2021037972A1
(en)
|
2019-08-27 |
2021-03-04 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
EP4025712A1
(en)
|
2019-09-05 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method of treatment and pronostic of acute myeloid leukemia
|
GB201913030D0
(en)
|
2019-09-10 |
2019-10-23 |
Francis Crick Institute Ltd |
Treatment of hr deficient cancer
|
KR102100163B1
(en)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
Compositions of Prevention or Treatment of Keloid or Hypertrophic scar
|
EP4034151A1
(en)
|
2019-09-27 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
EP3825408A1
(en)
|
2019-11-19 |
2021-05-26 |
FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. |
Methods of multi-species insect pest control
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
AR120773A1
(en)
|
2019-12-18 |
2022-03-16 |
Novartis Ag |
DERIVATIVES OF 3-(5-METHOXY-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONE AS REDUCERS OF THE ACTIVITY OF WIZ PROTEIN
|
US20230279394A1
(en)
|
2019-12-18 |
2023-09-07 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
BR112022013589A2
(en)
|
2020-01-08 |
2022-09-13 |
Regeneron Pharma |
TREATMENT OF PROGRESSIVE OSSIFYING FIBRODYSPLASIA
|
US20210222128A1
(en)
|
2020-01-22 |
2021-07-22 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
US20230070181A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
WO2021163079A1
(en)
|
2020-02-10 |
2021-08-19 |
Biomarin Pharmaceutical Inc. |
Virus-free cell cultures
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
IL310900A
(en)
|
2020-03-19 |
2024-04-01 |
Avidity Biosciences Inc |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
KR20230005244A
(en)
|
2020-04-20 |
2023-01-09 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Biologically Active Dry Powder Compositions and Methods of Making and Using The Same
|
US20210332364A1
(en)
|
2020-04-28 |
2021-10-28 |
Phyzat Biopharmaceuticals, Lda |
siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
US20210348167A1
(en)
|
2020-05-09 |
2021-11-11 |
Phyzat Biopharmaceuticals, Lda |
siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
|
JP2023526529A
(en)
|
2020-05-19 |
2023-06-21 |
アンスティテュ・クリー |
Methods of Diagnosis and Treatment of Cytokine Release Syndrome
|
AU2021278356A1
(en)
|
2020-05-27 |
2022-11-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct CAR T cells to an antigen of interest
|
EP4157288A2
(en)
|
2020-06-02 |
2023-04-05 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
EP3919062A1
(en)
|
2020-06-02 |
2021-12-08 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
CA3179113A1
(en)
|
2020-06-03 |
2021-12-09 |
Paul Holzer |
Selection and monitoring methods for xenotransplantation
|
US20230235326A1
(en)
|
2020-06-05 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
JP2023528663A
(en)
|
2020-06-09 |
2023-07-05 |
ジェネトン |
Treatment of Hereditary Dilated Cardiomyopathy
|
CA3185499A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
GB202009292D0
(en)
|
2020-06-18 |
2020-08-05 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of disease caused by type IV collagen dysfunction
|
US20230218608A1
(en)
|
2020-06-18 |
2023-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
US20230305023A1
(en)
|
2020-06-25 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
EP4172370A1
(en)
|
2020-06-30 |
2023-05-03 |
Lunglife Ai, Inc. |
Methods for detecting lung cancer
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
WO2022023576A1
(en)
|
2020-07-30 |
2022-02-03 |
Institut Curie |
Immune cells defective for socs1
|
EP4210722A1
(en)
|
2020-09-07 |
2023-07-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods of treatment of inflammatory bowel diseases
|
JP2023544016A
(en)
|
2020-09-30 |
2023-10-19 |
パイオニア ハイ-ブレッド インターナショナル, インコーポレイテッド |
Rapid transformation of monocot explants
|
GB202017244D0
(en)
|
2020-10-30 |
2020-12-16 |
Nat Univ Singapore |
Methods to extend health-span and treat age-related diseases
|
EP4247952A2
(en)
|
2020-11-23 |
2023-09-27 |
Phyzat Biopharmaceuticals, Lda. |
Sina molecules, methods of production and uses thereof
|
CN116710471A
(en)
|
2020-12-15 |
2023-09-05 |
诺维信公司 |
Mutant host cells with reduced cell motility
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
WO2022164796A1
(en)
|
2021-01-26 |
2022-08-04 |
California Institute Of Technology |
Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
EP4291898A1
(en)
|
2021-02-12 |
2023-12-20 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method for prognosis and treating a patient suffering from cancer
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
EP4322937A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve the anti-tumoral activity of macrophages
|
EP4328313A1
(en)
|
2021-04-21 |
2024-02-28 |
Jichi Medical University |
Adeno-associated virus virion for treating ornithine transcarbamylase deficiency
|
MX2023012608A
(en)
|
2021-04-30 |
2023-11-03 |
Kalivir Immunotherapeutics Inc |
Oncolytic viruses for modified mhc expression.
|
JP2024519888A
(en)
|
2021-05-28 |
2024-05-21 |
上海瑞宏迪医薬有限公司 |
Recombinant adeno-associated virus with capsid mutation and its application
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
WO2022269518A2
(en)
|
2021-06-23 |
2022-12-29 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
US11593428B2
(en)
|
2021-07-08 |
2023-02-28 |
Bank Of America Corporation |
System and method for detecting errors in a task workflow from a video stream
|
WO2023006765A1
(en)
|
2021-07-26 |
2023-02-02 |
Boehringer Ingelheim International Gmbh |
Treatment and prevention of alcoholic liver disease
|
EP4381069A1
(en)
|
2021-08-02 |
2024-06-12 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
CA3227511A1
(en)
|
2021-08-06 |
2023-02-09 |
Lætitia LINARES |
Methods for the treatment of cancer
|
EP4388122A1
(en)
|
2021-08-16 |
2024-06-26 |
F. Hoffmann-La Roche AG |
E3 ubiquitin ligase (ube3a) protein targets
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023111173A1
(en)
|
2021-12-16 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
|
WO2023111196A1
(en)
|
2021-12-16 |
2023-06-22 |
Singapore Health Services Pte. Ltd. |
Treatment and prevention of glomerular disease
|
WO2023122805A1
(en)
|
2021-12-20 |
2023-06-29 |
Vestaron Corporation |
Sorbitol driven selection pressure method
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
US12004476B2
(en)
|
2022-01-26 |
2024-06-11 |
Monsanto Technology Llc. |
Cotton variety 20R750B3XF
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
WO2024003350A1
(en)
|
2022-06-30 |
2024-01-04 |
Universite De Strasbourg |
Combination therapy for melanoma
|
EP4299742A1
(en)
|
2022-06-30 |
2024-01-03 |
Université de Strasbourg |
Combination therapy for melanoma
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
EP4311546A1
(en)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Combination therapy for myopathies
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
GB202212077D0
(en)
|
2022-08-18 |
2022-10-05 |
Tribune Therapeutics Ab |
Agents that inhibit ccn ligand-induced signalling for treating disease
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056659A1
(en)
|
2022-09-13 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Method for treating prostate cancer and other epithelial cancers
|
WO2024059618A2
(en)
|
2022-09-13 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed tgfbr shrnas
|
WO2024059824A2
(en)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024089609A1
(en)
|
2022-10-25 |
2024-05-02 |
Ablynx N.V. |
Glycoengineered fc variant polypeptides with enhanced effector function
|
WO2024110458A1
(en)
|
2022-11-22 |
2024-05-30 |
Institut Curie |
Lnc-znf30-3 as cancer biomarker and therapeutic target
|